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Abstract 
Ewing sarcoma is a highly aggressive pediatric cancer characterized by a 
chromosomal translocation leading to the chimeric ETS transcription factor EWS-
FLI1 in 85% of cases.  
We have performed gene expression analysis to identify genes regulated at the 
transcriptional level by EWS-FLI1. To elucidate which of these are direct targets of 
EWS-FLI1 chromatin immunoprecipitation followed by sequencing (ChIP-seq) was 
performed. Integrative bioinformatic analysis revealed that EWS-FLI1 directly binds to 
50% of E2F target genes in Ewing Sarcoma. Furthermore, several E2F factors were 
also found to be directly regulated by EWS-FLI1. Since E2F family members regulate 
cell cycle progression, regulation of E2F target genes by EWS-FLI1 might be a major 
pathway of cell cycle deregulation in Ewing Sarcoma. Therefore, we studied the 
functional interaction of EWS-FLI1 with E2F.  
Ten arbitrarily chosen EWS-FLI1/E2F candidate targets including E2F3, RAD51, 
GEMIN4 and ATAD2 were chosen for an in-depth promoter activity analysis. We 
confirmed direct EWS-FLI1 promoter binding (ChIP-PCR) and observed decreased 
reporter activity for all ten studied promoters upon knockdown of EWS-FLI1 by RNAi. 
Furthermore, the study of promoter occupancy by different E2F family members 
revealed that silencing of EWS-FLI1 results in the exchange of activating E2F3 for 
repressive E2F4 on the promoters of their jointly regulated target genes. Importantly, 
testing E2F3 promoter occupancy on wildtype and ETS motif mutated promoter 
constructs in Ewing sarcoma cell lines revealed that binding of E2F3 to its target 
promoters is dependent on an intact ETS binding site. Mutation of the ETS motif 
resulted in decreased binding of E2F3.  
These data suggest a model in which EWS-FLI1 actively recruits an activating E2F 
factor thereby replacing a repressing E2F factor and in which EWS-FLI1 binding is 
essential for E2F binding.  
Strikingly, the functional E2F/ETS transcriptional module detected in Ewing Sarcoma 
for the chimeric ETS factor EWS-FLI1 was found in TMPRSS2-ERG expressing 
prostate cancer cells. Our findings therefore suggest that this mechanism might be 
also relevant to other ETS fusion driven cancers.  
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Zusammenfassung 
Ewing Sarkome sind hoch aggressive pediatrische Tumore, die sich durch eine 
chromosomale Translokation auszeichnen, welche in einem ETS Transkriptionsfaktor 
resultiert.  
Wir führten Genom weite Expressionsanalysen durch um transkriptionell regulierte 
Zielgene von EWS-FLI1 zu identifizieren. Um herauszufinden welche davon direkt 
reguliert werden, wurden Chromatin Immunoprezipitationen gefolgt von 
Sequenzierung (ChIP-seq) durchgeführt. Bioinformatische Analyen zeigten dass 
EWS-FLI1 an 50% der E2F Zielgene bindet. Darüber hinaus sind einige E2F 
Faktoren ebenfalls direkt durch EWS-FLI1 reguliert. Da E2F Faktoren den Zellzyklus 
regulieren, könnte die Regulierung von E2F Zielgenen durch EWS-FLI1 ein Weg 
sein, auf dem der Zellzyklus im Ewing Sarkom dereguliert wird. Auf Grund dessen 
untersuchten wir die funktionelle Interaktion zwischen EWS-FLI1 und E2F. 
Zehn zufällig ausgewählte Zielgene deren Promotoren von EWS-FLI1 und E2F 
gebunden waren, unter anderem E2F3, RAD51 und ATAD2, wurden in detaillierten 
Promoteranalysen durch Luziferase Reporter Assays in Kombination mit 
Mutationsanalysen für die EWS-FLI1 und E2F DNA Bindungsstellen studiert. Alle 
Promotoren der untersuchten Zielgene zeigten nach Knock-down von EWS-FLI1 
verminderte Aktivität. Durch ChIPs konnten wir die direkte Bindung von EWS-FLI1 
and die oben genannten Promotoren zeigen. Weiters konnten wir durch eine Analyse 
der Promoter Belegung demonstrieren, dass durch den Knock-down von EWS-FLI1 
ein aktivierender E2F Faktor, E2F3, durch einen reprimierenden, E2F4, ausgetauscht 
wird. Interessant ist, dass dieser Austausch nur bei intakter ETS Bindungsstelle 
funktioniert, nicht aber wenn EWS-FLI1 nicht mehr an den Promoter binden kann. 
Die Mutation der ETS Bindungsstelle resultierte in reduzierter E2F3 Bindung.  
Unsere Daten stehen mit einem Modell in Einklang, in welchem EWS-FLI1 aktiv 
E2F3 zu Promotoren von gemeinsamen Zielgene rekrutiert und dadurch den 
reprimierenden Faktor E2F4 verdrängt. Dabei ist die Bindung von EWS-FLI1 
essentiell für diesen Vorgang.  
Besonders hervorzuheben ist, dass dieser Mechanismus auch in einer TMPRSS2-
ERG expremierenden Prostatakarzinom Zelllinie, nicht aber in einer nicht ETS-
Fusion exprimierenden Zelllinie, gezeigt werden konnte.  
10 
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1 Introduction 
1.1 Ewing Sarcoma 
Ewing Sarcoma is the second most common bone tumor after osteosarcoma in 
children and young adults with a peak incidence at the age of 15 [1]. It arises most 
frequently in bones, preferentially in the long bones of the extremities, pelvis, chest 
wall and spine [2]. Less than 10% of tumors originate in the soft tissue [3]. Ewing 
Sarcoma is slightly more common in males and Caucasians and hardly occurs in 
Asian and African individuals [2]. Approximately 15-25% of patients present with 
visible metastasis at diagnosis. It is supposed that patients without overt metastases 
harbor micro-metastases. This assumption is based on the fact that patients with 
primary tumor resection who do not receive a systemic chemotherapy relapse with 
distal metastases in about 90% of cases [3-5]. Primary metastasis usually occurs in 
lungs, bone, bone marrow but rarely in lymph nodes, the liver or the central nervous 
system [1]. Previously, when patients were not treated with chemotherapy, the 
survival rate was less than 10%. After the implementation of multimodal treatment 
regimens, including chemotherapy followed by surgery, if applicable, or radiotherapy, 
a long term survival rate >60% for patients with localized disease at diagnosis was 
achieved [5]. Still, patients who present with metastasis can only be cured in less 
than 25% of cases [6].  
Ewing Sarcoma is a member of the Ewing Sarcoma family of tumors which includes 
Askin’s tumor and peripheral neuroectodermal tumors (pPNET), all of which harbor 
the same chromosomal translocations which will be discussed in the following 
chapter [4]. pPNET and Ewing Sarcoma have high expression levels of the cell 
surface glycoprotein CD99. In contrast to pPNET, Ewing Sarcoma largely lacks 
neural features [7, 8]. Histologically, Ewing Sarcoma is a small blue round cell tumor 
with high nuclear to cytoplasmic ratios. The cells have scant, weakly eosinophilic 
cytoplasm, indefinite cytoplasmic borders and round nuclei with regularly distributed 
finely granular chromatin and low mitotic activity. The cytoplasm typically contains 
glycogen appearing in periodic-acid-Schiff-positive diastase-digestible granules. 
Strong expression of the glycoprotein CD99 is present in 90-100% of Ewing Sarcoma 
[1, 6]. 
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James Ewing first described Ewing Sarcoma in 1921 as a “diffuse endothelioma of 
the bone” arising in the blood vessels of the bone tissue with a clear discrimination 
from myeloma or osteosarcoma, the latter mainly due to its responsiveness to 
radiotheraphy [9]. In the last decades, the cell of origin of Ewing Sarcoma was 
controversially discussed, but mesenchymal [10-13] and neural crest derived 
progenitor cells [14-16] are considered the most promising candidates. Studies by 
Riggi et al. and Castillero-Trejo showed that the introduction of EWS-FLI1 in murine 
mesenchymal progenitor cells (MPS) or unselected primary murine bone marrow 
cells resulted in Ewing Sarcoma like tumors in immunocompromised mice [10, 12]. 
Riggi et al. further showed that the expression of EWS-FLI1 in human mesenchymal 
stem cells (MSC) induces a genome expression profile highly overlapping with that of 
Ewing Sarcoma [17]. Vice versa Tirode et al. showed that the knock down of EWS-
FLI1 in Ewing Sarcoma cell lines results in a gene expression profile similar to that of 
mesenchymal progenitor cells and that sustained EWS-FLI1 silencing induces the 
capability to differentiate into several lineages [13]. Kauer et al. recapitulated these 
results in a larger study comparing the gene expression signature of several EWS-
FLI1 silenced Ewing Sarcoma cell lines with human MPC expression profiles [11]. On 
the other hand there is evidence for a neural crest cell of origin. Lipinski et al. 
described neuroectodermal surface antigens on Ewing Sarcoma cell lines, such as 
ganglioside GD2, a marker of neuroectodermal tissues and tumors [14]. In a gene 
expression profiling study Staege et al. revealed that genes expressed in neural 
tissues or during neuronal differentiation are highly expressed in Ewing Sarcoma 
[16]. Furthermore, von Levetzow et al. showed that the expression of EWS-FLI1 in 
undifferentiated human neural crest stem cells (hNCSC) and their neuro-
mesenchymal stem cell progeny resulted in altered expression of known and novel 
EWS-FLI1 target genes. More importantly gene expression profiling studies revealed 
that the Ewing Sarcoma signature is more similar to the gene expression signature of 
hNCSC than any other normal tissue, including MSC [15].  
Taken together, compelling evidence for both theories has been obtained, but a 
conclusive answer to the question of histogenetic origin is still missing. This may be 
explained by the findings of Takashima et al. who revealed that neurally-derived 
MSCs are present in the bone marrow of the developing mouse, and of Lee et al. 
who demonstrated that neural crest stem cells contain mesenchymal lineage 
plasticity. This suggests that Ewing Sarcoma arises from a neurally-derived MSC or a 
neural crest stem cell with mesenchymal potential [3, 18, 19].  
1.1.1 EWS-FLI1 
Ewing Sarcoma is characterized by a chromosomal translocation leading to the 
fusion of EWS and an ETS transcription factor. In 85% of cases the t(11;22)(q24;q12) 
translocation combines EWS (Ewing Sarcoma breakpoint region 1) on chromosome 
22 with FLI1 (Friend leukemia virus integration site 1) on chromosome 11 [20, 21]. 
This results in a very potent oncogenic transcription factor EWS-FLI1 comprising the 
FLI-1 ETS DNA binding domain and the transactivation domain of EWS [22].  
 
 
Figure 1: Translocation between Chromosome 11 and 22 leads to EWS-FLI1 fusion gene. The 
reciprocal translocation between chromosomes 11 and 22 results in the formation of an EWS-FLI1 
fusion gene that consisits of the the N-terminal transcriptional regulatory domain of EWS and the ETS 
DNA-binding domain from FLI1 [1]. 
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1.1.2 EWS 
The EWS protein belongs to the FET family of proteins, which includes EWS, 
FUS/TLS and TAF15 [23]. Interestingly, all members of the FET family are involved in 
genomic rearrangements with transcription factors in several human sarcomas and 
leukemias, leading to the expression of an aberrant transcription factor. Full-length 
EWS, like the other family members, is an RNA-binding protein, playing an important 
part in RNA transcription, mRNA maturation, processing of small non-coding RNAs, 
RNA transport and DNA repair [23, 24]. Due to the fusion with FLI1, and other 
members of the ETS transcription factors family (see 1.1.3), EWS loses its C-terminal 
RNA binding domain but maintains its N-terminal domain, containing several repeats 
of serine-tyrosine-glycine-glutamine rich sequences [4, 23]. This kind of repeats 
resembles transcriptional activation domains in transcription factors, and fusion of 
this domain to a DNA binding domain results in a strong transcriptional activator [4, 
25].  
1.1.3 FLI1 
FLI1 is a member of the ETS family of transcription factors [26]. ETS proteins 
regulate gene expression in a variety of tissues by the binding of their DNA-binding 
ETS domain to promoters and enhancers and recruiting other components of the 
transcription machinery. The major characteristic of the ETS family members is the 
highly conserved ETS domain responsible for recognition of a common core binding 
motif 5’GGA(A/T)-3’, for EWS-FLI1 in the context of a CGGAAG motif [11, 26]. This 
conserved domain consists of three α-helices on a small four-stranded, antiparallel β-
sheet scaffold. Besides FLI1, the following proteins belong to the ETS transcription 
factor family: ERG, FEV, GABPA, ETV1-ETV8, ETV3L, ELK1-4, ERF, ETS1-2, 
SPDEF, ELF1-5, EHF, SPI1, SPIB and SPIC [26]. Several members of this family are 
fusion partners of EWS in Ewing Sarcoma, or are involved in oncogenic gene 
rearrangements in prostate cancer (as will be discussed in chapter 1.4.). 
Furthermore, the fusion of ETV6 with RUNX1 results in a chimeric transcription factor 
in acute lymphoblastic leukemia, underlining the importance of ETS transcription 
factors in human malignancies [21, 27, 28]. The expression of FLI1 is normally limited 
to hematopoietic and neural crest lineages. In Ewing Sarcoma rearrangement with 
EWS causes aberrant expression of chimeric FLI1 from the constitutively active EWS 
promoter [4].  
15 
 
1.1.4 Gene regulatory mechanisms of EWS-FLI1 
Because EWS-FLI1 is a transcription factor with a very potent transactivation domain 
fused to a DNA binding domain, it is expected to act rather like a transcriptional 
activator. However, EWS-FLI1 activates and represses comparable numbers of 
target genes. Yet whereas repressed genes mainly annotate to differentiation and 
cell communication, EWS-FLI1 activated genes are involved in cell cycle regulation 
and proliferation. Thus, the fusion protein appears to combine, by different 
mechanisms, two key functions of oncogenic transformation in one molecule 
stimulated proliferation and differentiation blockade. Kauer et al. demonstrated that 
EWS-FLI1 activated genes are significantly enriched in ETS binding motifs in their 
promoter sequences, whereas the ETS binding motif was clearly under-represented 
in EWS-FLI1 repressed promoters. This finding suggests a different, possibly indirect, 
mode of target gene repression by EWS-FLI1 [11].  
EWS-FLI1, for example, up-regulates NKx2.2, which is a transcription factor 
harboring both transcriptional activation and repression domains dependent on the 
cellular context. In Ewing Sarcoma gene expression profiling revealed that NKX2.2 
functions only as a repressor and that its expression signature overlaps with the 
EWS-FLI1 down-regulated signature. Furthermore linking transcriptional profiling with 
ChIP-on-chip data demonstrated that a significant portion of the NKX2.2-repressed 
gene expression signature was directly mediated by NKX2.2 binding [29-31]. Since 
NKX2.2 is an EWS-FLI1 activated gene, the repressive signature of EWS-FLI1 
seems to be, at least partially, mediated through NKX2.2. 
While in the above described mechanism EWS-FLI1 indirectly represses its target 
genes via up-regulation of a repressive factor, our lab previously reported a direct 
mechanism of target gene repression via the master regulator FOXO1. We found that 
EWS-FLI1 directly represses FOXO1 on the transcriptional level and via activation of 
CDK2 and AKT on the post-translational level. Gene expression profiling showed a 
significant overlap between EWS-FLI1 repressed and FOXO1 activated genes. 
Activation and targeting of FOXO1 to the nucleus resulted in reduced proliferation 
and clonogenicity of Ewing Sarcoma cells [32].  
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The work described in this thesis focuses on EWS-FLI1 induced mechanisms for 
gene activation and hence the above mentioned examples are not discussed further. 
Several mechanisms of target gene activation used by EWS-FLI1 have been 
described in the past. These include direct target gene activation through binding to 
its promoter, indirect activation via deregulation of an upstream regulator (see for 
example ID2 chapter 1.3, which is indirectly and directly activated), combinatorial 
binding with a cofactor to a target gene promoter or direct protein – protein 
interactions. I will discuss target gene activation through direct protein interaction in 
the following chapter 1.1.4.1 and will give an example of combinatorial binding in the 
below paragraph.  
Molecular analysis revealed that a number of EWS-FLI1 target genes contain ETS 
and AP-1 binding motifs within near proximity. Gel shift assays were used to study 
binding of Fos-Jun and EWS-FLI1 to the uridine phosphorylase (UPP) promoter and 
showed co-operative binding to ETS and AP1 tandem elements in the UPP promoter. 
Furthermore DNA binding of Fos-Jun complexes enhances binding of EWS-FLI1. 
While complex formation of Fos-Jun, binding of the complex and recruitment of EWS-
FLI1 to DNA could be shown, a direct interaction between Fos-Jun and EWS-FLI1 
could not be demonstrated. Interestingly, this cooperative promoter occupancy was 
also observed for other ETS family members, which participate in gene fusions in 
Ewing Sarcoma, but not for other ETS factors [33].  
1.1.4.1 EWS-FLI1 target gene activation trough interaction partners 
Among the various possible mechanisms used by EWS-FLI1 to modulate target gene 
expression, only few examples of direct protein-protein interactions are known. One 
such example is NR0B1, which was identified to physically interact with EWS-FLI1 
using a yeast two-hybrid screen. Mutations of NR0B1, which disrupt the association 
with EWS-FLI1, lead to an abrogated oncogenic transformation and also have 
transcriptional consequences. This suggests that the interaction between NR0B1 and 
EWS-FLI1 may mediate the transformed phenotype of Ewing Sarcoma [34]. 
Furthermore, in a study by Kinsey et al., transcriptional profiling data from three 
Ewing sarcoma cell lines in the presence and absence of EWS-FLI1 were analyzed 
and revealed NR0B1 (also known as DAX1) to be the most consistently EWS-FLI1 
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up-regulated gene and to be expressed in primary tumors [29]. NR0B1 is an orphan 
nuclear receptor that is important for adrenal gland development and was, until this 
study, not demonstrated to be involved in oncogenesis [35]. Comparison of the 
transcriptional profiles of NR0B1 and EWS-FLI1 revealed an overlap of regulated 
genes. Kinsey et al. further analyzed the genome-wide binding pattern of EWS-FLI1 
and NR0B1 using ChIP-on-chip and revealed that they bind in a large number to the 
same genes implying they co-ordinately modulate gene expression [29].  
Another and perhaps more general gene regulatory mechanism used by EWS-FLI1 is 
its association with several proteins of the basal transcription machinery. Among 
them are RNA polymerase II and its subunit hsRPB7 [36, 37]. While wildtype EWS 
binds to hyperphosphorylated RNA polymerase II and subsequently attracts splicing 
factors, EWS-FLI1 binds hyperphosphorylated RNA polymerase II but lacks the 
ability to recruit splicing factors [36]. CREB-binding protein (CBP) functions as 
transcriptional co-activator and tumor suppressor, binding of EWS-FLI1 to the amino-
terminal region of CBP leads to loss of interaction between CBP and nuclear-receptor 
transcriptional activity [38]. RNA helicase A (RHA) is not only part of the basal 
transcription machinery, but also part of the posttranscriptional RNA metabolism [39, 
40]. RHA was identified to directly interact with EWS-FLI1 and modulates EWS-FLI1 
transcription and anchorage-independent cell growth. Moreover RHA and EWS-FLI1 
bind to target gene promoters of EWS-FLI1 like ID2, which showed enhanced activity 
upon overexpression of RHA. Toretsky et al. conclude that RHA interacts with EWS-
FLI1 as a transcriptional cofactor to enhance its function [41]. 
1.2 Cell Cycle deregulation in Ewing Sarcoma 
Deregulation of the cell cycle and resulting sustained proliferation is one main 
hallmark of cancer and absolutely necessary for tumor growth and progression. 
Accordingly it is not surprising that several key regulators of the cell cycle are 
deregulated in Ewing Sarcoma. Kauer et al. reported that most of the EWS-FLI1 
activated genes annotate to cell cycle GO terms. In addition they revealed that in 
EWS-FLI1 activated promoters the E2F consensus binding motif is the second most 
common transcription factor binding motif after ETS, implying a cooperativity between 
EWS-FLI1 and E2Fs, which are known to play an important role in cell cycle 
regulation [11].  
In the following chapters I will discuss the phases of cell cycle and its regulators, with 
a specific focus on E2F factors and their regulators, the pocket proteins, to underline 
the importance and complexity of this regulatory network. In chapter 1.3 I will focus 
on the mechanisms used by EWS-FLI1 to enhance cell proliferation and therefore 
tumor growth.  
1.2.1 Cell cycle 
Continuous proliferation is maybe the most important trait of cancer. Normal tissue 
carefully controls the division and proliferation of cells by growth promoting and 
arresting signals, yet in cancer these signals are deregulated leading to sustained 
proliferation of cancerous cells [42]. Therefore, our knowledge of cell cycle regulation 
is essential for our understanding of cancer promotion.  
The cell cycle can be divided into interphase and mitosis, which includes prophase, 
metaphase, anaphase and telophase. In the mitotic phase, the daughter 
chromosomes are separated and the cells are divided (cytokinesis). While mitosis 
and cytokinesis last only about an hour and cells usually divide every 24h, the cells 
stay most of the time in the interphase, in which the chromosomes are decondensed 
and distributed throughout the nucleus. The interphase consists of G1, S and G2 with 
G1 and G2 representing the gaps in the cell cycle between mitosis and DNA 
synthesis (S phase). In the G1 phase, cells are preparing for DNA synthesis while at 
G2 cells prepare for mitosis. Cells in the G0 phase are not actively cycling. [43, 44]  
 
Figure 2: The stages of cell cycle. The cell cycle is divided into four phases: M (mitosis), S(DNA 
synthesis) and G1 and G2 [43].  
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1.2.2 Cell cycle regulation 
Cell cycle progression is a highly complex regulatory system controlled by several 
mechanisms. If these mechanisms are impaired unscheduled proliferation and, as a 
consequence, cancer initiation occurs. In this chapter I will give an overview of the 
major regulators of cell cycle which are often impaired by EWS-FLI1, as will be 
discussed in chapter 1.3. 
The key regulators of cell cycle maintenance are cyclin dependent kinases (CDK) in 
association with their activating subunits, cyclins. CDKs are serine and threonine 
protein kinases activated at specific time points in the cell cycle [45, 46]. While CDKs 
are expressed throughout the whole cell cycle, their activating partners, the cyclins, 
are synthesized and degraded at specific time points during the cell cycle and 
thereby periodically activating CDKs [45, 47]. Prior to progression into the next 
phase, the cyclin of the current phase has to be degraded and the subsequent cyclin 
has to be synthesized [44]. According to current knowledge in mammalian cells, 11 
CDK and 9 CDK-like genes are expressed, with only a few of them being involved in 
cell cycle regulation [47, 48] including three interphase CDKs (CDK2, CDK4, CDK6,) 
and a mitotic CDK (CDK1). The ten cell cycle associated cyclins belong to four 
groups, the A-, B-, D- and E- cyclins [45, 49]. Cyclins D1, D2 and D3 form a complex 
with CDK4 and CDK6 thereby stimulating the G1 phase entry. Progression from G1 
to S phase is promoted by association of cyclin E with CDK2. During S phase, cyclin 
A forms a complex with CDK2, which is exchanged for CDK1 in late G2 and early M 
to initiate M phase. CDK1 and cyclin B form the complex required for further 
regulation of mitosis [47]. In addition to the well established network of the above 
mentioned CDK/cyclin complexes, a few further complexes were suggested to play a 
role in cell cycle or gene regulatory mechanisms. CDK3/cyclinC was demonstrated to 
initiate the G0-G1 transition via phosphorylation of pRB [50]. CDK10 is supposed to 
be involved in G2-M transition and was demonstrated to associate with the N-
terminal domain of Ets2, which in turn regulates CDK1 [51].  
 Figure 3: Overview of CDK and Cyclin complexes through the cell cycle. CDK4–cyclinD, CDK6–
cyclinD and CDK3–cyclinC complexes regulate the G0–G1 transition and the early phases of G1 by 
phosphorylating the retinoblastoma protein (pRb). CDK2–cyclinE complexes complete phosphorylation 
of pRb. CDK2–cyclinE complexes are as well involved in the G1–S transition. During S phase CDK2 
associates with cyclin A. CDK1 participates in the S–G2 and G2–M transitions by binding to cyclin A 
followed by binding to cyclin B. CDK-activating kinase (CAK) phosphorylates, and presumably 
activates, all cell-cycle CDKs. CAK, a protein complex formed of CDK7, CyclinH and Mat1, is a 
substrate for CDK8–CyclinC (filled arrows). CDK10 and CDK11 might be involved in mitosis. Cyclin F 
might be required for entry into G1 and Cyclin G is implicated in the DNA damage response during the 
G2–M transition. Well described interactions are indicated by open arrows. Dotted arrows indicate 
interactions based on preliminary data [48]. 
Beside activation of CDKs by binding of their regulatory subunits, the cyclins, CDKs 
are controlled by phosphorylation by CAK [44].  
In addition, CDK inactivation is regulated via CDK inhibitors (CKI) which bind to 
CDKs alone or to the complex. Currently, two CKI families are known, the INK4 
family with p15 (INK4b), p16 (INK4a), p18 (INK4c) and p19 (INK4d) and the Cip/Kip 
family including p21 (Waf1, Cip1), p27 (Cip2) and p57 (Kip2). CKIs themselves are 
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under control of internal and external signals. [47]. For example, the expression of 
p21 is regulated by the tumor suppressor p53, which is important in the DNA damage 
checkpoint [49].  
By their classification as kinases, active CDK/cyclin complexes phosphorylate their 
substrates. CDK4 or CDK6 and D-type cyclins phosphorylate members of the pocket 
protein family, including Rb, p107 and p130 [48]. Phosphorylation of Rb leads to a 
disruption of its complex with the histone deacetylase proteins and the transcription 
factors of the E2F family and DP-1, which activate genes necessary for S phase 
progression like CDC25, cyclin A or cyclin E. Hyperphosphorylated pRB remains 
throughout the cell cycle under the control of CDK2/cyclin E [47].  
 
Figure 4: Regulation of the G1/S transition: In G0 cells E2F-DP is bound to p130, the main pocket 
protein in this phase, and thereby inactive. In G1 E2F-DP is bound to Rb. Formation of CDK4 
CDK6/cylin D complexes and initial Rb phosphorylation result from mitogenic signalling and 
subsequent cyclin D synthesis. Partially phospohorylated Rb is still bound to E2F/DP but they can 
already transcribe cyclin E, which then activates CDK2. CDK2 in the following phosphorylates and 
completely inativates Rb. E2F is therefore released and able to induce transcription of genes involved 
in G1/S transition and DNA replication initiation. INK4a and waf1/kip can inhibit CDK4/6/cyclin D 
CDK2/cyclin E, respectively. [49]  
Figure 4 summarizes the involvement of Rb into the complex network of CDKs and 
cyclins. In the following two chapters I will discuss the importance of the tumor 
suppressor Rb and the transcription factor family E2F.  
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1.2.3 E2F family of transcription factors 
The E2F family of transcription factors consists of eight genes, which are transcribed 
into nine proteins and jointly regulate cell cycle progression [52-54]. Traditionally the 
members are divided into transcriptional activators (E2F1-3A, B) and transcriptional 
repressors (E2F4-8) [54-57] although recent studies reveal that this categorization is 
limited [58]. E2F1, E2F2 and E2F3a, E2F3b contain a transcriptional activating 
domain at their C-terminus and are associated exclusively with pRB [57, 59]. While 
E2F3b is constitutively expressed throughout the cell cycle like E2F4 and E2F5, 
E2F1-3a levels increase upon cell cycle entry [57]. Although E2F1-5 proteins 
comprise the same pocket protein binding domain, their interaction partner varies. 
E2F4 and E2F5 interact with p130, while p107 is exclusively bound by E2F4, which is 
also associated with pRB. E2F6-8 do not bind pocket proteins but act as 
transcriptional repressors [56, 59]. E2F1–6 require dimerization with members of the 
differentiation-regulated transcription factor-1 polypeptide (DP) family to form 
functional transcription complexes on DNA. E2F7 and 8 lack a dimerization domain 
but comprise tandem repeats of an E2F DNA binding domain [60, 61].  
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Figure 5: E2F family members. All members of the E2F family share the core domains that mediate 
DNA binding or dimerization with DP (encompassing both the leucine zipper (LZ) and marked Box 
(MB) motifs). Sequences that are required for transcriptional activation and pocket-protein binding are 
only present in E2F1–E2F5. E2F1, E2F2 and E2F3a+b share a canonical basic nuclear localization 
signal (NLS) that is absent in E2F4 and E2F5, which have nuclear export signals (NES). E2F6, like 
E2F7 and 8 (not shown), is lacking a pocket protein binding domain but is able to recruit Ring1 and 
YY1 binding protein (RYBP) - and therefore the polycomb complex [62].  
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E2F1–3a function as transcriptional activators when released from 
hyperphosphorylated pocket proteins Rb1 and RBL1/p107 and form complexes with 
histone acetyltransferases (HATs) p300 and CBP [63]. Alternatively, they act by 
recruiting the HATs Tip60 and GCN5 to their target gene loci through their essential 
cofactor transactivation/transformation-domain associated protein (TRRAP) [64-66]. 
Repressor E2Fs (E2F4 and 5) are localized in the nucleus when bound to the 
hypophosphorylated retinoblastoma (Rb) like protein RBL2/p130, which appear to be 
involved in the repression of E2F-responsive genes by assembling transcriptional 
repressor complexes, including histone deacetylases (HDACs) and/or mSIN3B, the 
chromatin remodeling complex SWI/SNF and histone methyltransferases [67, 68].  
On the basis of these transcriptional properties, the transcriptional upregulation of 
E2F-responsive genes during the G1/S-phase transition is conferred by the 
replacement of repressor E2Fs with activator E2Fs at the E2F-binding element in 
their responsive gene promoters [59]. 
As already mentioned, E2F transcription factors bind to a number of genes such as 
cyclin A and E, DNA or polymerase subunits. Binding of activating E2Fs to the 
promoter regions results in transcription of genes necessary for S phase entry and 
enables cell cycle progression. This happens only under conditions in which cell 
cycle integrity is sustained. In case of for example DNA damage; Rb will stay in a 
complex with E2F and will not allow progression of the cell cycle until DNA is 
repaired. Following repair, Rb is hyperphosphorylated and releases E2F from the 
complex, allowing transcription of target genes [69].  
1.2.4 Pocket proteins 
The retinoblastoma gene Rb1 was the first member of the pocket proteins to be 
identified. Its discovery was based on its mutation or loss in retinoblastoma, a finding 
that has been also been discovered in a large number of other cancers. It was one of 
the first genes which provided evidence that the loss of a gene provokes tumor 
formation which subsequently led to the concept of tumor suppressor genes [70]. 
Due to sequence similarities, two further members of the pocket protein family have 
been identified, RBL1 and RBL2 which code for p107 and p130 proteins, respectively 
[71].  
 Figure 6: pRB, p107 and p130 homology. A) The small pocket domain is the central feature of RB 
family proteins. The large pocket is the minimal growth suppressing domain able to bind E2Fs. B) 
p107 and p130 harbor also a kinase inhibitory site, a cyclin binding site and a B-domain insertion [71]. 
The small pocket is the central feature of the pocket protein family and consists of the 
A and B domains that are conserved both across species and among the related 
proteins. The spacer region between these two domains varies in length and is not 
conserved. p107 and p130 contain cyclin binding sites within this linker region [71, 
72]. This spacer region allows for the assembly of the two domains into a pocket like 
structure [69]. The pocket was previously thought to be the minimal region in Rb 
sufficient for binding of viral oncoproteins such as adenovirus E1A, simian virus 40 
large T antigen and human papillomavirus E7 [72]. It was later discovered that those 
viral proteins contain a peptide motif called LXCXE, which they share with several 
cellular proteins often involved in chromatin regulation [71]. Proteins interacting with 
the pocket domain disrupt the binding of Rb to the E2F transcription factor family [72].  
The large pocket consists of the small pocket and the C-terminal domain, which is not 
necessary for viral protein binding. The large pocket, in turn, is necessary for E2F 
binding which results in inactivation of E2F dependent transcriptional activity [73]. 
E2Fs do not harbour a LXCXE motif but interact with Rb through a distinct site from 
histone deacetylases (HDACs), allowing the assembly of an HDAC-Rb-E2F 
repressor complex. Pocket proteins interact with HDAC1-3, which remove acetyl 
groups from histone tails, thereby promoting the necessary nucleosome formation to 
form a repressing complex on E2Fs [74].  
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1.3 EWS-FLI1 target genes involved in cell cycle regulation 
As described in the last chapters the cell cycle is regulated by a large number of 
factors, which are themselves tightly regulated. Deregulation of those factors and 
mechanisms results in sustained proliferation and, consequently, tumor growth. 
EWS-FLI1, like other oncogenes interferes with this regulatory system by repression 
of cell cycle inhibitors and activation of cell cycle promoting factors. In the following 
chapter I will discuss some of the known factors involved in EWS-FLI1 mediated 
aberration of the cell cycle (Fig. 7). 
 
Figure 7: Overview of cell cycle deregulation in Ewing Sarcoma [75] 
Depletion of EWS-FLI1 in Ewing Sarcoma cell lines leads to decreased cell 
proliferation, increased apoptosis and cell cycle arrest [76]. It is suggested that this is 
achieved through hypophosphorylation and thereby inactivation of Rb induced by 
EWS-FLI1 knockdown. Furthermore, it was shown that the regulatory proteins p27 
and p57 were increased, while the cell cycle promoting cyclin D1 and CDK2 were 
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decreased upon EWS-FLI1 depletion. These aberrations, together, may result in a 
deregulation of the cell cycle [76, 77].  
Evidence for a direct repression of p21 in Ewing Sarcoma cell lines by binding of 
EWS-FLI1 to a putative ETS transcription factor binding site within the p21 promoter 
was published by Nakatani et al. [78] - which is contrary to our findings, which 
strongly indicate the involvement of p53 in the regulation of p21 expression by EWS-
FLI1 [79]. Nevertheless, EWS-FLI1 represses p21, either directly or via p53, in that 
way eliminating a cell cycle inhibitor.  
The most common genetic aberration in Ewing Sarcoma, apart from the 
translocation, is deletion of the CDKN2A (p16) locus resulting in the loss of p16 and 
p14ARF expression [75, 80]. It has been reported that between 13 and 39% of Ewing 
Sarcoma patients harbor a deletion of this locus [80]. Notably, CDKN2B maps to the 
same chromosomal region as CDKN2A (p15) resulting in the simultaneous loss of 
p15 and p16. Deletion of this locus is associated with poor overall survival [75].  
p53 is mutated or truncated in 50% of all cancers [81], but only in 10% of Ewing 
Sarcoma and this subset of patients has been reported to show poor outcome [82, 
83]. p53 itself is under control of MDM2 and p14ARF. While MDM2 alterations are 
extremely rare in Ewing Sarcoma, the frequent homozygous loss of CDKN2A deletes 
p14ARF, a positive regulator of p53 [75].  
A further regulator of cell cycle is the transcription factor c-MYC which has been 
shown to induce the expression of cyclins D1, D2 and CDK4 thereby stimulating G1 
phase progression. In addition, c-MYC is able to increase E2F2 and cyclin A2 levels, 
both active in S phase. Dauphinot et al. demonstrated that besides cyclin D1, CDK4, 
Rb and p27, c-MYC is constantly highly expressed in Ewing Sarcoma cell lines [75, 
84]. However, c-MYC is not only driving proliferation through activation of cell cycle 
stimulating agents, but it is also upregulating ID2, which in turn is also a directly 
activated target of EWS-FLI1. ID2 was shown to interact with the tumor suppressor 
Rb sustaining it in its inactive state and unable to inhibit cell cycle progression [85, 
86].  
Although the deregulation of the cell cycle in Ewing Sarcoma has been studied for 
years and decades and already a number of altered key players have been found, 
the mechanisms have not yet been resolved for all of them.  
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1.4 ETS fusion driven cancers – Prostate cancer 
Although this thesis focuses on Ewing Sarcoma there is evidence supporting the 
notion that deregulated pathways and mechanisms are shared with other ETS fusion 
driven cancers including prostate cancer. 
Prostate cancer is the second most commonly diagnosed cancer in the United States 
and the second cause of cancer mortality in men [87]. Although age, environmental 
factors such as smoking or alcohol consumption, as well as Afro-American origin are 
well described risk factors, genetic alterations play an important role in prostate 
cancer development [88]. Apart from hereditary genetic aberrations, like mutations in 
the androgen receptor genes, the majority of prostate cancers is caused by 
spontaneous mutations and gene rearrangements. Recently it has been shown that 
more than 50% of prostate cancers contain gene rearrangements resulting in fusion 
genes [27, 88, 89]. The first fusion genes described in prostate cancer were fusions 
of the 5’ untranslated region of TMPRSS2 to the ETS transcription factors ERG and 
ETV1 [90]. ERG is overexpressed in 72% of cases of prostate cancer thereby making 
it the most prominent oncogene in this kind of cancer [89]. TMPRSS2 is a serine 
protease secreted in response to androgen exposure from prostate epithelial cells. 
Fusions of this gene to ETS or other transcription factors lead to an androgen 
induced oncogene [27, 89, 91]. Additional androgen responsive 5’ partners of ERG 
are SLC45A3, HERPUD1 and NDRG1, wherein SLC45A3 also fuses with ELK4, 
ETV1, ETV5 and FLI1 and TMPRSS2 fuses also with ETV1, ETV4 and ETV5 [27, 
92]. Additional partners for ETV1 include HERV-K22q11.23, C15orf21 and 
HNRPA2B1, and for ETV4 KLK2 and CANT1 were identified as fusion partners [89]. 
In 1-2% of prostate cancers, ETS transcription factors are not involved, but RAF 
kinase gene fusions were found, namely SLC45A3-BRAF, ESPRP1-RAF1 and 
RAF1-ESPR1 [93]. Several studies outlined that patients with a TMPRSS2-ERG 
fusion have a significantly worse outcome and that ETS fusion positive cancers have 
a significantly dissimilar transcriptional profile from ETS fusion negative prostate 
cancers, implying that these two subsets represent two different kinds of cancer [91]. 
40 to 80% of PSA screened prostate cancers harbour an ETS-fusion, while 20-60% 
do not and are lacking a biomarker or prognostic factor. An analysis for top meta-
outliers revealed SPINK1 to have outlier expression in ETS fusion negative prostate 
cancers and to be associated with clinical recurrence of prostate cancer [94]. Figure 
8 summarizes the different gene rearrangements present in prostate cancer and 
outlines again the significant over representation of ETS gene fusions.  
 
Figure 8: Prostate cancer gene fusion classification. Gene fusions are divided into three groups 
ETS fusion gene positive, negative and RAF kinase fusions. Percentages reflect the estimated 
frequency of each subtype according to the literature [27].  
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Aim of the thesis 
A recent study from our lab demonstrated that approximately the same number of 
genes is simultaneously up and down-regulated by EWS-FLI1. The most striking 
difference was that the results showed an enrichment of consensus ETS binding 
sites in the promoters of activated genes, while the ETS binding motif was clearly 
under-represented in EWS-FLI1 repressed promoters. Furthermore, we could show 
that the second most common transcription factor binding motif after ETS in EWS-
FLI1 activated genes was the E2F consensus site.  
Since E2Fs are major regulators of cell cycle progression, which in turn is a hallmark 
of cancer, we aimed to functionally define the transcriptional network of factors 
binding to EWS-FLI1 regulated E2F target genes, and to molecularly define the mode 
of action used by EWS-FLI1 and E2F and their consequences on cell cycle 
progression.  
The specific aims were:  
 To physically confirm the simultaneous binding of EWS-FLI1 and members of 
the E2F family to EWS-FLI1 activated target genes by ChIP-seq for FLI1, 
E2F3 and E2F4 in collaboration.  
 To define by mutation analysis EWS-FLI1, E2F3 and E2F4 target sites within 
ChIP-seq hits in the promoters of EWS-FLI1 target genes and to analyse the 
functional consequences in reporter gene assays performed in Ewing 
Sarcoma cells in the presence and absence of EWS-FLI1. 
 To characterize the composition of transcription factor complexes occupying 
the promoters of these genes with respect to E2F3, E2F4, hyper- and 
hypophosphorylated pocket proteins RB1, RBL1/p107, and RBL2/p130 in a 
time resolved manner after modulation of EWS-FLI1. 
 To modulate the individual and combined expression of EWS-FLI1, E2F3, and 
E2F4 by RNA interference and/or ectopic expression, and to test for the 
functional consequences on promoter activity of these genes and cellular 
proliferation/cell cycle. 
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 To study if co-localization and co-occupancy of promoters by EWS-ETS and 
E2F factors would also be found in Prostate Cancer cell lines harboring a 
similar gene fusion resulting in a transcription factor which binds as well to 
ETS binding motifs. 
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2 Material and Methods 
2.1 Material 
2.1.1 Media 
Luria Broth (LB): 
1% Trypton 
1% NaCl 
0,5% Yeast-extract 
sterilization by autoclaving 
For Agar Dishes: 
1% Trypton 
1% NaCl 
0,5% Yeast extract 
1,5% Agar 
Ampicillin was supplied after cooling down the autoclaved agar to 50°C.  
Pour out the solution into petri-dishes. 
Terrific Broth (TB): 
900ml H20  
12g Tryptone 
24g Yeast-extract 
4ml Glycerol 
sterilization by autoclaving 
the following filer-sterilized supplement was added prior to use: 
32 
 
100ml of 0,17M KH2PO4, 0,72M K2HPO4 
NZY+ Broth:  
10 g of NZ amine (casein hydrolysate) 
5 g of yeast extract 
5 g of NaCl 
pH 7.5 
per liter 
sterilization by autoclaving 
the following filer-sterilized supplements were added prior to use: 
12.5 ml of 1 M MgCl2 
12.5 ml of 1 M MgSO4 
20 ml of 20 % (w/v) glucose  
RPMI 1640 with GlutaMAXTm-I: Invitrogen, Groningen, Netherlands 
10% fetal calf serum (FCS Gold, PAA Laboratories, Linz, Austria) and 100000 
Units/l penicillin / streptomycin (PAA Laboratories, Linz, Austria) 
Opti-MEM: Invitrogen, Groningen, Netherlands 
DMEM, High Glucose, GlutaMAX™: Invitrogen, Groningen, Netherlands 
 4500 mg/L glucose, 4mM L-glutamine and 110 mg/L sodium pyruvate 
10% fetal calf serum (FCS Gold, PAA Laboratories, Linz, Austria) and 100000 
Units/l penicillin / streptomycin (PAA Laboratories, Linz, Austria) 
2.1.2 Reagents: 
Trypsin / EDTA: PAA Laboratories, Linz, Austria 
Accutase: PAA Laboratories, Linz, Austria 
Puromycin: Sigma, St. Louis, USA 
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Ampicillin: Biomol, Hamburg, Germany 
Doxycycline: Sigma, St. Louis, USA 
Blasticidin: Invitrogen, Groningen, Netherlands 
Zeocin: Cayla, Toulouse, France 
Dimethyl pimelimidate dihydrochloride (DMP): Sigma, St. Louis, USA 
 
2.1.3 Buffers 
PBS: 137mM NaCl; 3mM KCl; 6,5mM Na2HPO4-2H2O; 1,5mM KH2PO4
TBS: 50mM Tris, 150mM NaCl, pH 7,5 
TBS-T: 50mM Tris, 150mM NaCl, 0,1% Tween 20; pH 7,5 
2x sample buffer:  
20% (v/v) glycerol 
6% ß-mercaptoethanol 
3% SDS 
125mM Tris-Cl pH 6,8 
a few bromphenol blue crystals 
Laemmli buffer: 
15,1g Tris 
72g glycine 
25ml 20% SDS 
per 1 liter 
Transfer buffer: 
14g glycine 
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3g Tris 
20% methanol 
per 1 liter 
Ponceau S staining solution (10x stock): 
2g Ponceau S 
30g trichloroacetic acid 
30g 5-sulfosalicylic acid 
ad 100ml 
Loading Dye: 
4M Urea 
80mM EDTA 
10% Saccharose 
0,25% BPB 
TBE: 
 5,4g Tris Base 
 2,75g Boric Acid 
 2ml 0,5M EDTA/pH8 
 per 1 liter  
DMP solution: 
0.01032g DMP/2 ml Na-Borate 
IP-Lysis Buffer: 
50 mM Tris (pH 8,0) 
400 mM NaCl 
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0,5% NP40 
1 tablet Protease Inhibitor cocktail “complete” (Roche, Basel, Switzerland) disvolved 
in 50ml PBS  
0,2M NaBorate pH(9): 20g in 500ml H20 
125mM Tris: 25ml 1M +75ml H20 
0,1M Glycin: 3,7g in 500ml H20 
Buffer 1A for Chromatin Immunoprecipitation: 
0.1% SDS 
1% Triton X-100 
2mM EDTA 
20mMTris HCl 
500mM NaCl 
pH8.1 
 
Blocking solution: 
Licor blocking reagent (Roche, Basel, Switzerland) in maleic acid buffer (100mM 
Maleic Acid, 150 mM NaCl, pH= 7.5, sterile). 
 
2.1.4 Bacterial strains 
JM109: endA1, recA1, gyrA96, thi, hsdR17 (rk-, mk+), relA1, supE44, ∆(lac-proAB), 
[F’, traD36, proAB, laclqZ∆M15], (Promega, Madison, USA) 
Sure2 Supercompetent Cells: e14-(McrA-) Δ(mcrCB-hsdSMR-mrr)171 endA1 
gyrA96 thi-1 supE44 relA1 lac recB recJ sbcC umuC::Tn5 (Kanr) uvrC [F’ 
proAB lacIqZΔM15 Tn10 (Tetr) Amy Camr], (Stratagene, La Jolla, USA) 
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2.1.5 Cell lines 
ASP14: Ewing tumor cell line established from A673 parental cell line by Javier 
Alonso (Laboratorio de Patología Molecular de Tumores Sólidos 
Infantiles, Departamento de Biología Molecular y Celular del Cáncer, 
Instituto de Investigaciones Biomédicas, Madrid, Spain) (expresses 
EWS-FLI1 type 1, p53 mutant). Inducible cell line, Doxycycline induces 
shRNA against EWS-FLI1 [95] 
VCaP: TMPRSS2-ERG expressing prostate cancer cell line established from a 
vertebral bone metastasis from a patient with hormone refractory 
prostate cancer by the lab of Pienta KJ [96]. 
HeLa: Cell line established from epidermoid carcinoma of the cervix by the 
group of Gey GO [97].  
2.1.6 Plasmids 
2.1.6.1 Existing plasmids 
pMaxGFP Used for monitoring transfection efficiency. Amaxa GmbH, 
Cologne, Germany 
pGL4.10:  Firefly luciferase reporter vector. Promega, Madison, USA 
pCMV:  CMV promoter based mammalian expression (constructed 
by Suzanne Baker, John’s Hopkins, Baltimore) 
pcDNA3-E2F1: Mammalian expression vector encoding human E2F1 (Gift 
from Nevins JR, Department of Molecular Genetics and 
Microbiology, Institute for Genome Sciences and Policy, 
Duke University Medical Center, NC, USA) 
pBSK-E2F3: Mammalian expression vector encoding human E2F3 (Gift 
from Nevins JR, Department of Molecular Genetics and 
Microbiology, Institute for Genome Sciences and Policy, 
Duke University Medical Center, NC, USA) [98] 
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pcDNA3-E2F4: Mammalian expression vector encoding human E2F4 
(Constructed by Claude Sardet, Whitehead Institute, 
Cambridge, MA, USA) 
pRETROSuperScrambled: pSUPER-based retroviral mammalian expression vector. 
(Gift from Eiji Hara, The Cancer Institute, Japanese 
Foundation for Cancer Research, Tokyo, Japan) 
shE2F3:  Adtrack based shRNA expression plasmid under the control 
of U6 promoter encoding shRNA against E2F3 (Gift from 
Nevins JR, Department of Molecular Genetics and 
Microbiology, Institute for Genome Sciences and Policy, 
Duke University Medical Center, NC, USA) 
shE2F1: Adtrack based shRNA expression plasmid under the control 
of U6 promoter encoding shRNA against E2F1 (Gift from 
Nevins JR, Department of Molecular Genetics and 
Microbiology, Institute for Genome Sciences and Policy, 
Duke University Medical Center, NC, USA) 
2.1.6.2 Plasmids established in the course of this thesis 
pGL4.10-ATAD2:  ATAD2 reporter gene construct that encodes ATAD2 
Promoter Region -368 / +202 
pGL4.10-E2F3:  E2F3 reporter gene construct that encodes E2F3 Promoter 
Region -272 / 327 
pGL4.10-RRM2:  RRM2 reporter gene construct that encodes RRM2 
Promoter Region -463 / 191 
pGL4.10-RFC2:  RFC2 reporter gene construct that encodes RFC2 Promoter 
Region -400 / 87 
pGL4.10-VRK1:  VRK1 reporter gene construct that encodes VRK1 Promoter 
Region -269 / 100 
pGL4.10-MFL1IP:  MFL1IP reporter gene construct that encodes MFL1IP 
Promoter Region -251 / 70 
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pGL4.10-GEMIN4:  GEMIN4 reporter gene construct that encodes GEMIN4 
Promoter Region -275 / 87 
pGL4.10-CDK2:  CDK2 reporter gene construct that encodes CDK2 
Promoter Region -118/+458 
pGL4.10-SKP2:  SKP2 reporter gene construct that encodes SKP2 Promoter 
Region -240 /348 
pGL4.10-RAD51:  RAD51 reporter gene construct that encodes RAD51 
Promoter Region -186 / 164 
pGL4.10-PRKC1:  PRKC1 reporter gene construct that encodes PRKC1 
Promoter Region -169 / 235 
2.1.7 Oligonucleotides 
ChIP-PCR Primers: 
ATAD2 -1678/-1470 fwd: CCCAGACATTGCATTCTTCA 
ATAD2 -1678/-1470 rev: GAGGCCAATGAGAACAGAGC 
ATAD2 -350/-240 fwd: CAGGGGTGGGGAGGAGACGC 
ATAD2 -350/-240 rev: GAGCGGTGCGTAGCCCGTTT 
ATAD2 -117/18 fwd: GCCCGGCCTCCTTCGCTCTA 
ATAD2 -117/18 rev: GGCGCCACAAGCTCCGCGCCA 
ATAD2 26/129 fwd:  GAGCGCGGAAGAGCCAGAG 
ATAD2 26/129 rev:  GCTGCTGCGGAGAACCACCA 
E2F3 -1457/-1334 fwd: AAGGAGTCCTAGCCTGATCTGA 
E2F3 -1457/-1334 rev: TGAGGATTGCAACACCTTGA 
E2F3 -272/-149 fwd: TCAAGGAGGCCTATGCAAAT 
E2F3 -272/-149 rev: GGCCGCTACCTCCTTACTTC 
E2F3 -132/-62 fwd:  CGGGTTGAGGGGCGGGGATA 
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E2F3 -132/-62 rev:  TGCAACGGATTGCGAGGCGG 
E2F3 131/262 fwd:  CCAGAGCCCCGATTATTTTT 
E2F3 131/262 rev:  GCAGTCGGAGTTTCCAAGTC 
RAD51 -4270/-4017 fwd: AGGCAGGAGTATCGCTTGAA 
RAD51 -4270/-4017 rev: AGTGTGGTGGCTCACACTTG 
RAD51 -93/104 fwd: CGTCTTGGGTTAGCGCGCAG 
RAD51 -93/104 rev: GTTCCCAGCTGCACGCCTCG 
RAD51 -51/65 fwd:  ATCCGGGAGGCGGGGATACG 
RAD51 -51/65 rev:  TAGGGCTCGGTCTCTGGCCG 
RAD51 -51/106 fwd: ATCCGGGAGGCGGGGATACG 
RAD51 -51/106 rev: CAGTTCCCAGCTGCACGCCT 
RAD51 45/146 fwd:  CGGCCAGAGACCGAGCCCTA 
RAD51 45/146 rev:  TCGCTTGCCCCAGCCTTCTG 
GEMIN4 -3609/-3486 fwd: GGAGGCTACTGTGGAGACCA 
GEMIN4 -3609/-3486 rev: ATGACCCTGGACACTCAAGC 
GEMIN4 -236/-47 fwd: GTTACCGGGTGAGGGTGAAT 
GEMIN4 -236/-47 rev: GCAGTCCTCACGAACGAG 
GEMIN4 -153/8 fwd: GGTGCGGAGGGGTCTAGT 
GEMIN4 -153/8 rev: TTAGGCCTGCTCACAACCTC 
GEMIN4 -130/76 fwd: ACGTCCGGGTACCTGAGGGC 
GEMIN4 -130/76 rev: TCCGAGAACTCGAACGCGGC 
ChIP-PCR on promoter constructs Primers: 
pGL4.10 rev:   AACAGTACCGGATTGCCAAG  
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E2F3 fwd:   GCGTAAACCGTATCCCTTCA 
ATAD2 fwd:   CAGCAAGCAGGTGTCAACAG 
pGL4.10-GEMIN4 rev: CTCGAAGTACTCGGCGTAGG used with  
GEMIN4 -236/-47 fwd 
 
Site directed mutagenesis primers: 
ATAD2 Ets mt fwd: CGCAGCTCTGGCTCTTTATAGCTCCGAATTCTGGCGCC 
ATAD2 Ets mt rev: GGCGCCAGAATTCGGAGCTATAAAGAGCCAGAGCTGCG 
ATAD2 E2F mt fwd: CGCGCTCCGAATTCTGTTACCACAAGCTCCGCGC 
ATAD2 E2F mt rev: GCGCGGAGCTTGTGGTAACAGAATTCGGAGCGCG 
ATAD2 E2F mt fwd: CCCGCCGCCGTCCCTTACCAAAATTCCAAACGG 
ATAD2 E2F mt rev: CCGTTTGGAATTTTGGTAAGGGACGGCGGCGGG 
E2F3 Ets mt fwd: CATTGTCAGCAGCAGCTATATGGAGCCATTTTTCAGCTGCC 
E2F3 Ets mt rev: GGCAGCTGAAAAATGGCTCCATATAGCTGCTGCTGACAATG 
E2F3 Ets mt fwd: GAGAGGGGGCTCTATAGCGCCGGGCGG 
E2F3 Ets mt rev: CCGCCCGGCGCTATAGAGCCCCCTCTC 
RAD51 Ets mt fwd: GCGCGCAGGGCTATAGCGGGGAGAAGGCGG 
RAD51 Ets mt rev: CGCGCGTCCCGATATCGCCCCTCTTCCGCC 
RAD51 Ets mt fwd: GGAGAGTGCGGCGCTATACGAGGCGTGCAGCTG 
RAD51 Ets mt rev: CCTCTCACGCCGCGATATGCTCCGCACGTCGAC 
RAD51 E2F mt fwd: CTGGGCGAGAGGGTTTGTTAGGAATTCTGAAAGCCGCC 
RAD51 E2F mt fwd: GACCCGCTCTCCCAAACAATCCTTAAGACTTTCGGCGG 
GEMIN4 Ets mt fwd:  CCGCTGGGACCCCTATAGAGGGGCCGGGC 
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GEMIN4 Ets mt rev:  GGCGACCCTGGGGATATCTCCCCGGCCCG 
GEMIN4 Ets mt fwd:  GGGAGGGCTCTGCCTATAGGCGGCGCTGTGC 
GEMIN4 Ets mt rev:  CCCTCCCGAGACGGATATCCGCCGCGACACG 
GEMIN4 E2F mt fwd:  CGGCGCTGTGCGCTTGTTACGCTCGTTCGTGAGG 
GEMIN4 E2F mt rev:  GCCGCGACACGCGAACAATGCGAGCAAGCACTCC 
GEMIN4 E2F mt fwd:  CGTGCCGTGCGTCCCTTACCGCGTTCGAGTTCTC 
GEMIN4 E2F mt rev:  GCACGGCACGCAGGGAATGGCGCAAGCTCAAGAG 
MWG pGL-series Standard primers: 
pGL rev:  CTTTATGTTTTTGGCGTCTTCC 
pGL3 for: CTAGCAAAATAGGCTGTCCC 
 
2.1.8 Antibodies 
Anti-E2F3 (C-18): rabbit polyclonal antibody against the C-terminus 
of human E2F3. (Santa Cruz Biotechnology Inc., 
Santa Cruz, USA, sc-878).  
Western Blot Dilution: 1:400 
ChIP: 1,5µg per reaction 
Anti-E2F4 (C-20): rabbit polyclonal antibody against the C-terminus 
of human E2F4. (Santa Cruz Biotechnology Inc., 
Santa Cruz, USA, sc-866).  
Western Blot Dilution: 1:500 
ChIP: 1,5µg per reaction 
Anti-E2F1 (C-20): rabbit polyclonal antibody against the C-terminus 
of human E2F1. (Santa Cruz Biotechnology Inc., 
Santa Cruz, USA, sc-193).  
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Western Blot Dilution: 1:200 
ChIP: 1,5µg per reaction 
Anti-FLI1: rabbit polyclonal antibody against the C-terminus 
of human FLI1. (MyBiosource, San Diego, 
California, USA, MBS300723).  
Western Blot Dilution: 1:400 
ChIP: 3µg per reaction 
Anti-RB (C-15): rabbit polyclonal antibody against the C-terminus 
of human RB. (Santa Cruz Biotechnology Inc., 
Santa Cruz, USA, sc-50).  
Western Blot Dilution: 1:200 
ChIP: 3µg per reaction 
Anti-p130 (C-20): rabbit polyclonal antibody against the C-terminus 
of human p130. (Santa Cruz Biotechnology Inc., 
Santa Cruz, USA, sc-317).  
Western Blot Dilution: 1:200 
ChIP: 3µg per reaction 
Anti-p107 (C-18): rabbit polyclonal antibody against the C-terminus 
of human p107. (Santa Cruz Biotechnology Inc., 
Santa Cruz, USA, sc-318).  
Western Blot Dilution: 1:200 
ChIP: 3µg per reaction 
Anti-DP1 (K-20): rabbit polyclonal antibody against the N-terminus 
of human DP1. (Santa Cruz Biotechnology Inc., 
Santa Cruz, USA, sc-610).  
Western Blot Dilution: 1:200 
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ChIP: 3µg per reaction 
Anti-Rabbit IgD, DyLightTM800: Goat Anti-Rabbit antibody reacts with heavy 
chains of rabbit IgG and with light chains of most 
rabbit immunoglobulins (Pierce Biotechnology 
Inc., Rockford, USA).  
Dilution: 1:10000 
Anti-Mouse IgD, DyLightTM800: Goat Anti-Rabbit antibody reacts with heavy 
chains of mouse IgG and with light chains of most 
mouse immunoglobulins (Pierce Biotechnology 
Inc., Rockford, USA).  
Dilution: 1:10000 
 
2.2 Methods 
2.2.1 DNA Methods 
2.2.1.1 Cloning of gene reporter constructs 
PCR was performed for 25 cycles in a total volume of 50µl with 10pmol of the 
corresponding primers, 10mM dNTPs (Promega, Madison, USA), 5µl 5xPhusion 
HotstartII Buffer (Finnzymes, Espoo, Finland), 1µl Phusion Hotstart II (Finnzymes, 
Espoo, Finland) and 100ng of genomic DNA were used as a template. PCR products 
were digested with KpnI and NheI restriction enzymes (NEB, Ipswich, USA) using 
Buffer1 in the presence of BSA over night at 37°C. Gel purification was performed 
with ZymocleanTM Gel Recovery Kit (Zymo Research, Orange, USA). pGL4.10 was 
digested with KpnI and NheI and dephosphorylated with CIAP (NEB, Ipswich, USA) 
at 37°C for 30min.  
Ligation was performed overnight at RT with T4 Ligase and the provided T4 Ligase 
Buffer (Promega, Madison, USA).  
VRK1 was cloned using KpnI and HindIII and GEMIN4 with NheI and XhoI.  
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2.2.1.2 Site directed Mutagenesis 
Site directed Mutagenesis was performed using QuikChange® II Site-Directed 
Mutagenesis Kit (Stratagene, La Jolla, USA, 200523) according to manufacturer’s 
instructions. 
2.2.1.3 Transformation of competent E.coli (JM109) 
DNA transformation of competent E.coli JM109 (Promega, Madison, USA) was 
permormed according to manufacturer’s instructions. 
2.2.1.4 Transformation of competent E.coli (Sure2 Supercompetent Cells) 
DNA transformation of competent E.coli Sure2 Supercompetent Cells (Stratagene, La 
Jolla, USA, 200523) was permormed according to manufacturer’s instructions. 
2.2.1.5 Mini Prep 
2ml of 10mg/ml ampicillin containing LB were inoculated with a single colony and 
incubated overnight at 37°C with shaking. For Mini Preps the Quiagen MiniPrep kit 
(Quiagen, Austin, USA) was used according to the manufacturer’s instructions. 
2.2.1.6 Restriction digest of gene reporter plasmids 
500ng DNA of plasmids was digested with KpnI and NheI in Buffer1 (NEB, Ipswich, 
USA) in the presence of BSA at 37°C for 4h. Restriction reactions were analyzed on 
an 1% Agarose Gel. Plasmids containing the corresponding fragment were sent for 
sequencing.  
2.2.1.7 Sequencing 
Sequencing was done at MWG Biotech (Ebersberg, Germany). The sequences were 
blasted against the NCBI human genomic plus transcript database.  
2.2.1.8 Maxi Prep 
250ml of 10mg/ml ampicillin containing LB were inoculated with a preculture of the 
corresponding plasmid and incubated overnight at 37°C with shaking. For Maxi 
Preps, the Quiagen Endotoxin free MaxiPrep kit (Quiagen, Austin, USA) was used 
according to the manufacturer’s instructions. 
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2.2.1.9 Chromatin Immunoprecipitation followed by PCR: 
Chromatin Immunoprecipitation was performed using the MAGnifyTM Chromatin 
Immunoprecipitation System (Invitrogen, Groningen, The Netherlands) according to 
the manufacturers instructions with minor modifications. Cells were crosslinked with 
1% formaldehyde at room temperature for 10 minutes, the reaction was not stopped 
with Glycin. The cells were then sheared with a Bioruptor UCD200 4 times 7 minutes 
of alternating 30sec sonication and 30 sec break to achieve an average shearing size 
of 600bp. The antibodies used were: anti-FLI1 antibody (MyBiosource, San Diego, 
California, USA, MBS300723), anti-E2F3 (Santa Cruz Biotechnology, Santa Cruz, 
USA sc-878), anti-E2F4 (Santa Cruz Biotechnology Inc., Santa Cruz, USA, sc-866), 
anti-RB (Santa Cruz Biotechnology Inc., Santa Cruz, USA, sc-50) and anti-p130 
(Santa Cruz Biotechnology Inc., Santa Cruz, USA, sc-317). Please refer to 2.1.8. for 
the amounts of antibody used per ChIP. Washing steps after chromatin incubation 
with the Ab coupled beads were extended to 20min each, and an additional washing 
step between IP Buffer1 and 2, was applied using Buffer 1A (as described in 2.1.3.).  
PCR was performed for 35 cycles in a total volume of 30µl with 10pmol of the 
corresponding primers, 10mM dNTPs (Promega, Madison, USA), 5µl 5xPhusion 
HotstartII Buffer (Finnzymes, Espoo, Finland), 0.3µl Phusion Hotstart II (Finnzymes, 
Espoo, Finland) and 3µl of ChIP Eluate. Sybr Green PCR for ChIP on promoter 
constructs and pocket proteins was performed using Maxima™ SYBR Green/ROX 
qPCR Master Mix (Fermentas) according to manufacturer’s instructions. 
2.2.1.10 Chromatin Immunoprecipitation and Sequencing. 
Chromatin immunoprecipitation (ChIP) was performed using a ChIP-IT kit from Active 
Motif (Carlsbad, CA), following the manufacturer’s instructions with minor 
modifications. Briefly, A673 cells were crosslinked with 1% formaldehyde at room 
temperature for 15 minutes. The cells were then sheared with a VirSonic 100 
sonicator for 20 cycles of 10 x 1-second pulses.  The chromatin was 
immunoprecipitated overnight at 4°C.  The antibodies used were:  anti-FLI1 antibody 
(sc-356), and anti-E2F3 (sc-878) (Santa Cruz Biotechnology, Santa Cruz, CA).  A 
mixture of Protein-G and Protein-A agarose beads was used.  After reversal of 
crosslinking at 65oC overnight, the ChIP DNA was purified using spin columns 
provided by the kit.  For ChIP-seq, the ChIP DNA was prepared, amplified, and 
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analyzed on an Illumina G1 Genome Analyzer (San Diego, CA), following 
manufacturer’s protocols.  
 
2.2.2 Protein Methods 
2.2.2.1 SDS- Polyacrylamid Gel Electrophoresis 
The SDS- polyacrylamid gel consists of two different layers of gels, the stacking gel 
which is always a 6% gel and the separating gel which varies between 6 and 12,5%. 
Separating gel: 
 6% 8,5% 12,5% 
30%Acrylamid / 0,8% Bis 1,05ml 1,4ml 2,1ml 
H2O 2,625ml 2,275ml 1,575ml 
1,5M Tris pH8,8 1,25ml 1,25ml 1,25ml 
20% SDS 25µl 25µl 25µl 
10% APS 50µl 50µl 50µl 
TEMED 6µl 6µl 6µl 
Stacking gel: 
30%Acrylamid / 0,8% Bis 415µl 
H2O 1,7ml 
1M Tris pH6,8 315µl 
20% SDS 12,5µl 
10% APS 25µl 
TEMED 2,5µl 
The cell pellet was resuspended in PBS and the same amount of 2x Sample Buffer 
was added. After boiling the samples 10min at 95°C and centrifugation they were 
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loaded on the gel, which was run at 40mA till the bromophenol blue front was not 
visible any more.  
2.2.2.2 Western Blot 
The transfer unit, consisting of a sponge, three 3 pieces of 3MM paper, the gel, a 
nitrocellulose membrane, three 3 pieces of 3MM paper and a sponge (everything 
presoaked with transfer buffer), was put in the blotting stock. The transfer was run at 
400mA for 90min on ice. 
For a first staining, the membrane was incubated in PonceauS solution for 5 to 10min 
and scanned afterwards. To block unspecific binding, the membrane was incubated 
in 1% blocking solution for 1 hour at RT. The primary antibody was diluted in 0,5% 
blocking solution, added to the membrane and incubated overnight at 4%. The 
membrane was then washed twice with TBST for 10min and once with 0,5% blocking 
solution. The secondary antibody was diluted in 0,5% blocking solution, added to the 
membrane and incubated for 1 hour at RT: After washing the membrane three times 
with TBST and once with PBS for 15min each, it was scanned using the Li-cor 
Odysee Infrared Imaging System (Li-cor Biosciences, Lincoln, USA).  
2.2.2.3 Co-Immunoprecipitation with Ab-Crosslinking: 
For Co-Immunoprecipitation with Ab-Crosslinking Dynabeads (Invitrogen, Groningen, 
The Netherlands)) were incubated with the Ab over night at 4°C. After washing with 
0,2M Na-Borate (pH 9,0), the beads were crosslinked with the antibody using 
Dimethyl pimelimidate dihydrochloride (for solution preparation please refer to 2.1.3). 
Washing with  250 mM Tris and preelution using 0,1 M Glycine (pH 2.0); was 
followed by incubation of the cell lysate over night (IP lysis buffer as described in 
2.1.3) at 4°C. After washing with IP lysis buffer, elution was performed using 0,1 M 
Glycine (pH 2.0).  
2.2.3 Cell culture techniques 
A673 human cell line was routinely grown in DMEM, high glucose (4,5g/l), 
GlutaMAXTm-I medium (Invitrogen, Groningen, The Netherlands) supplemented with 
10% fetal calf serum (FCS Gold, PAA Laboratories, Linz, Austria), 100.000 U/l 
penicillin/streptomycin (PAA Laboratories, Linz, Austria) in 5% CO2 at 37°C. 
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2.2.3.1 Transfection 
Cells were seeded in a 75cm² flask to 50-80% confluency one day before 
transfection. DMEM medium was removed and cells were incubated in Opti-MEM I at 
least one hour prior to transfection. Transfection was performed with Lipofectamine 
and Plus reagent (Invitrogen, Groningen, The Netherlands) according to the 
manufacturer’s instructions in serum-free OptiMEM I medium (Invitrogen, Groningen, 
The Netherlands) using at most 4µg DNA. After incubation for 4 hours the serum-free 
medium was replaced by supplemented DMEM medium.  
2.2.3.2 Transfection for gene reporter assays 
Cells were seeded in a 24well plate to 20-30% confluency one day before 
transfection. DMEM medium was removed and cells were incubated in Opti-MEM I at 
least one hour prior to transfection. Transfection was performed with Lipofectamine 
and Plus reagent (Invitrogen, Groningen, The Netherlands) according to the 
manufacturer’s instructions in serum-free OptiMEM I medium (Invitrogen, Groningen, 
The Netherlands) using 50ng of the reporter gene plasmid, 50ng of pmaxGFP and 
150ng shRNA if used. After incubation for 4 hours, the serum-free medium was 
replaced by supplemented DMEM medium. If applied, 1µg/ml doxycycline was added 
48h after transfection. 
2.2.3.3 Reporter Gene Assays 
Gene repoter assays were performed 96h after transfection if doxycycline was 
applied, otherwise 48h after transfection. Reporter gene assays were performed 
using the Bright-GloTM Luciferase Assay System (Promega, Madison, USA) 
according to the manufacturer’s instructions.  
2.2.3.4 Cell Cycle Assay 
Cell Cycle analysis was performed using the CycletestTM Plus DNA Reagent Kit 
(Becton Dickinson, New Jersey, USA) according to manufacturers instructions.  
2.2.3.5 Double thymidine block 
Complete DMEM medium with 2mM thymidine was added to the cells for 16h, then 
the cells were washed twice with DMEM and incubated in normal DMEM for 8h, 
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followed by a second thymidine block for 16h. Cells were harvested and subjected to 
either cell cycle assay or ChIP.  
2.2.4 Bioinformatic Methods 
2.2.4.1 Gene Expression Analysis 
Microarray analysis. RNA was extracted at five timepoints, 0h, 18h, 36h, 53h, 72h, 
and subjected to microarray analysis where 0h marks the timepoint when doxycycline 
was added, and 18h the time point when modulation of EWS/FLI1 protein was first 
observed as determined by immunoblot analysis. RNA was hybridized to Affymetrix 
HGU-133-A2 arrays (Affymetrix, Inc., Santa Clara, CA). cRNA target synthesis and 
GeneChip® processing were performed according to standard protocols (Affymetrix, 
Inc., Santa Clara, CA). Processing of CEL files, normalizing and filtering was done in 
R statistical environment using Bioconductor packages [99]. Microarray data from the 
knockdown analysis was submitted to GEO – accession number: GSE27524.  Each 
time-point was replicated at least twice. 
Affymetrix CEL files were read into R statistical environment and normalized using 
the “gcrma” algorithm [100].  Probesets with very low expression values across all 
samples (R package “panp”) were filtered out. Subsequently, probesets associated 
with the same gene identifier were averaged and merged to one symbol, yielding 
12928 unique genes. Principal component analysis was performed using the GNU 
scientific library Singular Value Decomposition routines. Pearson correlation 
coefficients with |r| > 0.8 of comparing individual genes with the first three principal 
components were used to identify significantly correlated genes.   
2.2.4.2 Sequence Data Analysis 
Sequence reads were mapped to the human reference genome (NCBIv36, Hg18) 
using Illumina’s extended Eland alignment program. Reads starting at identical 
positions, as well as low quality reads with more than two deviations from the 
reference or an alignment score less than 25 were removed from the resulting 
datasets. Local read densities were then estimated by counting coverage of read-
events for each nucleotide in the genome, where the oriented reads were extended 
to the insert length (100bp), which was size-selected during library preparation. 
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P-values were used to identify significantly increased read densities. They were 
estimated based on the cumulative Poisson distribution, where the local emission 
coefficient (x) was estimated from input (non-IP) data using the average read 
densities of windows centered around x of sizes 1bp, 100bp, 1000bp, respectively.  
Of those, the most conservative (largest) estimate max  i(x) was used in order to 
minimize the false discovery rate.  Discrete enriched regions were identified using the 
following heuristic: a continuous stretch of DNA was called significantly enriched if 
the following conditions were met simultaneously: p < 10-9 anywhere within that 
region, and p<=10-6 everywhere else. Subsequently, distinct significant regions were 
merged into a single region if they were less than ½ fragment size (50bp) apart.  
Finally, regions determined in this way smaller than the median fragment length 
(100bp) were rejected.   
The discrete regions of enrichment were analyzed for conservation by reporting the 
maximum phast-score (vertebrate, 44-way conservation scores downloaded from 
UCSC, www.genome.ucsc.edu) within the discrete regions of enriched read density.  
2.2.4.3 Identification of putative EWS/FLI1, E2F3 regulatory target genes 
Putative regulatory targets of EWS-FLI1 and E2F3 binding were identified based on 
the closest gene heuristic, this is, for each binding site, the closest RefSeq transcript 
with a unique Entrez gene identifier was identified.  In cases where multiple RefSeq 
transcripts mapped to the same Entrez gene identifier, the longest transcript was 
selected.  Gene ontology analysis of the genes was made with custom in-house  
software. Pathway analysis was done using DAVID [101]. 
2.2.4.4 DNA Motif Analysis 
Coordinates of sequences similar to known transcription factor binding site motifs 
were identified using a matrix based approach [102]. The frequency of known motifs 
(Transfac 11.4 database) present in regions of enriched read density was counted 
and compared to their respective frequency in (a) the entire genome or (b) regions 
selected randomly from the genome. For (b), sequencing data for non-selected 
(input) DNA was used to generate the random location distribution. P-values for over-
representation were derived using (for a) Fisher’s exact test or (for b) by counting the 
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number of random iterations, where the frequency of a given motif in the random set 
was larger or equal to the frequency observed in the ChIP-seq dataset.  
Co-enrichment of other transcription factors around a given motif was estimated by 
enlarging a hit for that motif up- and downstream +/-100 bases, counting the number 
of co-occurrences and comparing this number to their respective frequency in the 
entire genome, again using Fisher’s Exact test to calculate P-values.  
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3 Results: 
3.1 Physical confirmation of simultaneous binding of EWS-FLI1 
and members of the E2F family 
In one of our earlier studies, Kauer et al. reported that ETS and E2F binding sites 
significantly co-occur on promoters of EWS-FLI1 activated genes [11]. To validate 
this co-binding, chromatin immunoprecipitation followed by DNA sequence analysis 
(ChIP-seq) was performed in collaboration with the lab of Paul Meltzer at the 
Genetics Branch, National Cancer Institute, NIH, USA with antibodies specific for 
EWS-FLI1, E2F3 and E2F4 in the A673 Ewing Sarcoma cell-line. Our decision to 
study E2F3 rather than E2F1 is primarily based on their induction in mesenchymal 
stem cells after EWS-FLI1 transduction in our own experiments and from Riggi et al. 
[17]. While E2F1 was only slightly induced in our own data and not at all in Riggi’s 
data, E2F3 was up regulated in both datasets. The basis for additionally analyzing 
E2F4 binding was the fact that E2F4 is the only E2F family member expressed in the 
presence and absence of EWS-FLI1. Since FLI1 is not expressed in Ewing Sarcoma 
cells a FLI1 antibody was used to precipitate EWS-FLI1.  
Short read sequencing generated 27 million EWS/FLI1 high quality sequence tags 
which uniquely aligned to the human genome, 12.5 million E2F3 tags and 9.5 million 
E2F4 tags. In addition, non-selected input DNA (13.5 million aligned tags) was 
sequenced in order to compensate for potential local bias in tag density.  
An analysis of tag densities identified 16386 EWS-FLI1, 4303 E2F3 and 1431 E2F4 
discrete binding regions with significantly (up to 100-fold) increased read densities. 
Both EWS/FLI1 and E2F3 binding regions demonstrated a high level of conservation 
in a 44-way vertebrate comparison (Figure 9). More than 90% of the E2F3 and E2F4 
binding regions had a maximum conservation score larger than 0.5, in 75% of 
regions the peak score within the region was at its maximum value 1. For EWS-FLI-1 
the corresponding numbers were 78% with conservation score larger than 0.5 and 
almost 60% with score 1. EWS-FLI1 binding sites in close proximity to transcription 
start sites (<4kb) showed an even higher conservation (83% >0.5, 65% score=1) as 
compared to distant binding sites (>4kb) (66% >0.5, 45% score=1). These values are 
significantly higher in comparison to randomized regions, where only approximately 
40% of regions reach a 0.5 peak conservation score, and 15% a score of 1.  
  
Figure 9: Genome wide characterization of the conservation score of binding sites. Fraction of 
binding regions with a maximal conservation smaller or equal to the value on the ordinate. E2F4 
binding regions are most highly conserved, over 80% of all regions show the highest level of 
conservation. EWS-FLI-1 binding regions, too, show a high degree of conservation, regardless of 
whether they are located within proximal promoter regions or in distal enhancer regions. As a 
reference, the random curve estimates the behavior of unselected regions in the genome, it was 
obtained by randomizing the location, but not the shape, of EWS-FLI-1 binding regions using the 
density of read tags from the input lanes to model the location probability distribution. 
Based on a “closest gene” heuristic, which associated each binding region to the 
closest gene regardless of distance, 3776, 1373 and 8204 unique gene identifiers 
were associated with E2F3, E2F4 and EWS-FLI1 binding sites, respectively.  
Strikingly more than 50% of the E2F3 binding regions overlapped with those of EWS-
FLI-1 (Figure 10), indicating that both factors frequently co-localize in the genome 
and, therefore, potentially interact in regulating their targets. The observed overlap 
was approximately 75-times more frequent than would have been attributable to 
mere chance when compared to a theoretical flat genomic background. 87% of E2F4 
binding regions were also occupied by E2F3 and EWS-FLI1.  
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Figure 10: Venn diagram of E2F3, E2F4 and FLI1 ChIP-Seq hits in the promoter region (<1kb +-
transcription start site) of target genes 
Individually, E2F3 as well as EWS-FLI-1 had a substantial bias towards binding 
within promoter regions (Figure 11): E2F3 and EWS-FLI-1 binding regions were 50 
fold (1419 of 4304) and 18 fold (2775 of the 16383 regions) more likely to be located 
within 1kb upstream of transcription start sites compared to an “average” 1kb region 
in the genome.  
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Figure 11: E2F3, E2F4 and EWS-FLI1 bind significantly to promoter regions. Enrichment of 
binding sites in the intergenic region (>4k), proximal promoter (<1k), intron and and exons.  
 
In accordance with the observed co-localization in the ChIP-seq data, an in silico 
analysis of transcription factor site recognition matrices revealed a very strong cross-
enrichment of E2F and ETS motifs [102]. Figure 12 shows the frequency of EWS-
FLI1 and E2F binding relative to ETS binding motifs. E2F3, E2F4 (not depicted in 
Figure 12) and EWS-FLI1 preferentially bind to regions with ETS binding sites.  
In addition, E2F motifs were 36-fold over-represented within EWS/FLI1 binding 
regions and ETS motifs were 60-fold over-represented within E2F3 binding regions. 
Simultaneous presence of the ETS motif with the E2F motif almost doubled the 
probability of observing E2F3 binding compared to promoters containing an E2F 
recognition motif only. 
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Figure 12: Genome wide preferred binding of E2F and EWS-FLI1 in regard to ETS binding 
motifs. The X-axis represents the E2F motif distance from the ETS motif in bps and the Y-axis 
represents the binding frequency of E2F3 and EWS/FLI1. 
3.2 EWS-FLI1 gene expression profile shows a better overlap with 
the E2F3 than with the E2F1 signature 
Gene expression profiles upon conditional EWS-FLI1 knockdown in A673 cells 
revealed that several E2F transcription factors belong to a class of genes early down 
regulated upon knock down of EWS-FLI1. Among the subgroup of activating E2F 
factors E2F1 and E2F3 were down regulated upon depletion of EWS-FLI1. Since a 
significant number of genes are co-operatively bound by EWS-FLI1 and E2F factors, 
we decided to analyse the overlap of the EWS-FLI1 signature with the signature of 
E2F1 and E2F3. We therefore performed knock downs of E2F1 and E2F3 in A673 
cell lines and subjected the cells to gene expression profiling. Comparison of the 
gene-expression profile upon conditional EWS-FLI1 knockdown with data from E2F1 
and E2F3 knockdowns in the same cell line revealed that 966 genes were down 
regulated upon EWS-FLI1 depletion (threshold -1), 1266 genes (threshold -0.7) were 
decreased upon knockdown of E2F3 and expression levels of 482 genes (threshold -
0.7) declined after E2F1 knockdown. While EWS-FLI1 activated genes mainly 
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annotate to cell cycle genes, E2F3 annotate to angiogenesis related clusters and 
E2F1 to extracellular space. 50 genes are activated by both EWS-FLI1 and E2F3 and 
annotate to cell cycle genes. The overlap of EWS-FLI1 and E2F1 genes is only about 
half (24 genes) which are related to disulfide bonds and extracellular space. Although 
224 genes are co-activated by the cell cycle factors E2F1 and E2F3, they are not 
annotated as cell cycle genes, but rather extracellular space and disulfide bonds. The 
data suggests, that E2F3 and EWS-FLI1 share a larger number of target genes 
compared to EWS-FLI1 and E2F1, and, even more important, EWS-FLI1 target 
genes and shared EWS-FLI1/E2F3 target genes both annotate to cell cycle genes. 
The fact that depletion of E2F3 or E2F1 did not result in significant changes in cell 
cycle associated genes, while EWS-FLI1 knock down, or combinatorial knock down 
of EWS-FL11 and E2F3 does, implies that EWS-FLI1 might be the major cell cycle 
regulator in Ewing Sarcoma.  
3.3 Validation of target genes using gene reporter assays 
The analysis so far indicated preferential co-localization of EWS-FLI1 and E2F3 on 
proximal promoters of activated genes, but regulatory activity of both factors in vitro 
remained to be shown. Therefore, promoter fragments of ten randomly selected 
genes with proximal EWS-FLI1, E2F3 and E2F4 binding regions were cloned into a 
luciferase reporter vector and tested for EWS/FLI1 dependent activity by firefly 
luciferase reporter assays in A673 cells. All ten constructs demonstrated a significant 
two- to three-fold reduction of the reporter activity 48 hours after conditional EWS-
FLI1 knockdown, while the promoter of an expressed gene without any EWS-FLI1 or 
E2F ChIP-seq signal and the empty vector control did not respond to EWS-FLI1 
modulation (Fig. 13). 
 
Figure 13: Firefly luciferase reporter assays for 10 arbitrarily chosen genes identified by ChIP-
seq as EWS-FLI1 and E2F target genes. Promoter fragments (CDK2:-122/+458; E2F3: -272/+327; 
RAD51: -186/+164; VRK1: -269/+100; RFC2: -400/+25; ATAD2:-368/+202; RRM2: -463/+191; 
GEMIN4: -275/+87; MFLI1P: -251/+70, SKIP2: -240/348) were cloned into the pGL4.10 vector 
(Promega) and tested for responsiveness to conditional EWS-FLI1 knockdown in A673 Ewing 
Sarcoma cells 48h after doxycycline induced EWS-FLI1 shRNA induction. As negative controls, 
promoter activities of an expressed gene that does not show a change in mRNA expression after the 
EWS-FLI1 knockdown (PRKCI: -139/265), and of the empty vector (pGL4.10) are shown. The Y-axis 
represents the promoter activity relative to control conditions. Means and standard deviations of at 
least three independent experiments, each performed in triplicate, are shown. 
3.4 Target gene selection 
Of the ten target genes (mentioned in chapter 3.3) which show ChIP-seq hits for 
EWS-FLI1, E2F3 and E2F4 and are down regulated upon knockdown of EWS-FLI1, 
we arbitrarily chose E2F3, RAD51, ATAD2 and GEMIN4 to study the interplay of 
EWS-FLI1 with E2F3 and E2F4. The promoter regions of these genes harboring an 
overlapping ChIP-seq hit for E2F3, E2F4 and EWS-FLI1 were cloned in a firefly 
luciferase gene reporter construct. Transcription factor binding sites (TFBS) within 
these regions were identified using the ConSite algorithm [103]. In silico analysis 
confirmed the Chip-seq data. Since several TFBS were found, a conservation score 
higher than 85% was used as a cut off criteria for E2F binding sites. For ETS binding 
sites the CGGAAG motif was also required. TFBS fulfilling these criteria were 
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mutated individually and simultaneously. The resulting constructs were tested in gene 
reporter assays and analyzed for their promoter occupancy by EWS-FLI1, E2F3 and 
E2F4. For E2F3 see chapter 3.5, for RAD51 3.6, for GEMIN4 3.7 and for ATAD2 3.8.  
E2F3 and RAD51 were studied in more detail to gain better insight into the regulatory 
mechanisms used by EWS-FLI1 and E2F factors.  
3.5 E2F3 is a direct target of EWS-FLI1 and E2Fs 
Previously published gene expression profiling data using the doxycycline inducible 
EWS-FLI1 shRNA cell line A673 before and after EWS-FLI1 knockdown, indicate that 
E2F3 is a target of EWS-FLI1 [11]. To further study the mechanisms of E2F3 
promoter regulation by EWS-FLI1, the promoter region of E2F3 was cloned in a gene 
reporter construct. Gene reporter assays were performed in A673 cells before and 
after knockdown of EWS-FLI1. Knockdown of EWS-FLI1 or mutation of the upstream 
located 96% scoring ETS-binding site led to a reduction of luciferase activity by 62%. 
While the mutation of the downstream 89% scoring ETS-binding site led only to a 
32% reduction in reporter activity, combinatorial mutation of both ETS-binding sites 
lead to a decrease of luciferase activity by 77% (Fig.14). Consequently we wanted to 
validate the direct binding of EWS-FLI1 to the E2F3 promoter using ChIP for EWS-
FLI1 followed by PCR. Binding of EWS-FLI1 to both ETS binding sites is 
demonstrated in Fig. 15, which shows it to be weakened (for the upstream TFBS) or 
decreased (for the downstream TFBS) upon knockdown of EWS-FLI1. A third PCR 
which covers an upstream promoter region of E2F3 without E2F or ETS binding sites 
shows no binding. These results indicate a direct regulation of E2F3 via the binding 
of EWS-FLI1. 
 Figure 14: E2F3 promoter study. Firefly luciferase reporter assays for E2F3 wildtype and 
mutant promoter construct. Promoter fragment (-272/+327) was cloned into the pGL4.10 vector 
(Promega) and tested for responsiveness to conditional EWS-FLI1 knockdown in A673 Ewing 
Sarcoma cells. ETS binding sites at -7/-5 and/or 207/209 were mutated. Fold changes in reporter 
activity of wild type and mutant E2F3 reporter constructs in the presence (+) and doxycycline-induced 
absence (-) of EWS/FLI1 48h after EWS/FLI1 shRNA induction. Y-axis presents promoter activity 
relative to untreated control conditions. Data represent means and standard deviations of at least 
three independent experiments, each performed in triplicate. 
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Figure 15: Occupancy of the E2F3 promoter by EWS-FLI1. To monitor binding of EWS-FLI1 to the 
promoter region of E2F3, chromatin immunoprecipitation was performed in A673 Ewing Sarcoma 
cells. Cells were either left untreated (+) for control, or were treated for 48h with doxycycline to induce 
knockdown of EWS-FLI1 (-). Two regions containing putative ETS binding sites (-123/62 and 131/262) 
and a region 1.4kb upstream of the TSS (-1457/-1334) not containing E2F or ETS binding sites were 
amplified. 
3.6 Combinatorial binding of EWS-FLI1 and E2F is necessary for 
RAD51 promoter regulation. 
As previously mentioned RAD51 was chosen for in depth promoter studies (see 
chapter 3.4). Therefore TFBS were analyzed and revealed a E2F binding site with a 
conservation score of 92% near the transcription start site (+5) and two ETS binding 
sites. The upstream ETS binding site had a conservation score of 92% and the 
downstream ETS TFBS of 86%. Gene reporter studies with wildtype and mutation of 
the ETS and E2F binding sites within the RAD51 promoter were performed in A673 
cells before and after knockdown of EWS-FLI1 (Fig. 16A). Depletion of EWS-FLI1 led 
to a reduction of promoter activity by 55%. While the single mutation of the ETS 
binding sites led to no or only slight reduction, the combinatorial mutation of both ETS 
binding sites resulted in a 45% reduction of transcriptional activity, indicating that 
both ETS binding sites are equally able to bind EWS-FLI1 and keep RAD51 active. 
However, mutation of the single E2F binding site resulted in similar luciferase activity 
as the wildtype construct, even in the absence of EWS-FLI1. Consequently, binding 
of a member of the E2F family is necessary for the regulation of RAD51 by EWS-
FLI1 and is therefore dependent on both EWS-FLI1 and E2F. Furthermore, the triple 
mutation of both ETS binding sites and the E2F binding sites showed no regulation in 
the presence and absence of EWS-FLI1 compared to the wildtype construct.  
Also we wanted to confirm the direct binding of EWS-FLI1 to the RAD51 promoter by 
ChIP. Figure 16B shows ChIP-PCRs for both ETS binding sites, the upstream TFBS 
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is bound by EWS-FLI1 in the presence of EWS-FLI1, but not in its absence. The 
downstream ETS binding site is bound in both conditions but significantly reduced in 
the EWS-FLI1 knockdown condition. The control PCR covering a RAD51 promoter 
fragment 4kb upstream of the transcription start site shows no binding of EWS-FLI1. 
As a consequence of these findings we suggest that EWS-FLI1 is directly regulating 
RAD51, but needs assistance from E2F family members.  
 
Figure 16: RAD51 promoter study. A) Fold changes in reporter activity of wildtype and mutant 
RAD51 reporter constructs in the presence (+) and doxycycline-induced absence (-) of EWS/FLI1 48h 
after EWS/FLI1 shRNA induction. ETS binding sites in the RAD51 promoter at -70/-68 and 81/83 and 
one E2F binding site in the RAD51 promoter at 8/11 were mutated. Y-axis presents promoter activity 
relative to untreated control conditions. Data represent means and standard deviations of at least 
three independent experiments, each performed in triplicate. B) To monitor binding of EWS-FLI1 to the 
promoter region of RAD51, chromatin immunoprecipitation was performed in A673 Ewing Sarcoma 
cells. Cells were either left untreated (+) for control, or were treated for 48h with doxycycline to induce 
knockdown of EWS-FLI1 (-). Two regions containing putative ETS binding sites (-93/104 and 45/146) 
and a region 4kb upstream of the TSS (-4270/-4017) not containing E2F or ETS binding sites were 
amplified 
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3.7 GEMIN4 promoter regulation by E2F and EWS-FLI1 
For GEMIN4, individual mutations of each of two ETS binding sites (at -176 and at -
92), and of one of two putative E2F binding motifs (at -70) only insignificantly (p= 
0,1068, p=0,4017 and p=0,065) reduced basal promoter activity in A673 cells. In 
contrast, ablation of the second E2F motif at +55, and combinatorial mutation of both 
ETS sites or both E2F sites significantly reduced GEMIN4 promoter activity to 
between 50-60% (p<0,01 and p<0,05). In all instances, the modulatory response to 
EWS/FLI1 knockdown lost significance, except for mutation of the ETS site at -92 
(Fig. 17). These results are compatible with both ETS and E2F sites being involved in 
GEMIN4 transcriptional regulation, and confirm the dependence of promoter 
response to EWS/FLI1 modulation on the loss of availability and binding of E2F3.  
 
Figure 17: GEMIN4 promoter study. Fold changes in reporter activity of wildtype and mutant 
GEMIN4 reporter constructs in the presence (+) and doxycycline-induced absence (-) of EWS/FLI1 
48h after EWS/FLI1 shRNA induction. ETS binding sites in the GEMIN4  promoter at -176/-178 and -
92/-90 and E2F binding sites at  -70/-68 and 55/57 were mutated. Y-axis represents promoter activity 
64 
 
relative to untreated control conditions. Data represent means and standard deviations of at least 
three independent experiments, each performed in triplicate. 
To verify the ChIP-seq results for EWS-FLI1 and E2F3, standard ChIP followed by 
PCR was performed for the GEMIN4 promoter. Reduction of promoter occupancy by 
EWS-FLI1 and E2F3 upon knockdown of EWS-FLI1 was demonstrated. A control 
region where both EWS-FLI1 and E2F3 should not bind shows no PCR product (Fig. 
18).  
 
Figure 18: Occupancy of theGEMIN4 promoter by EWS-FLI1 and E2F3. To monitor binding of 
EWS-FLI1 and E2F3 to the promoter region of GEMIN4, chromatin immunoprecipitation was 
performed in A673 Ewing Sarcoma cells. Cells were either left untreated (+) for control, or were 
treated for 48h with doxycycline to induce knockdown of EWS-FLI1 (-). Two regions containing 
putative E2F (-153/8 and -130/76) binding sites, one region containing putative ETS binding sites (-
136/-47) and a region 4kb upstream of the TSS neither containing E2F or ETS binding sites (-3609/-
3486) were amplified. 
3.8 Regulation of ATAD2 is dependent on EWS-FLI1 and E2F 
For ATAD2, individual mutation of either the single ETS core motif at position +33 or 
a highly conserved E2F site at -267 reduced the response by approximately 50%, 
while perturbation of a second E2F core motif at +14 lowered the intensity only by 
about 25% (Fig. 19). In all single mutation instances, the promoter fragments retained 
their responsiveness to EWS-FLI1 knockdown. In contrast, the triple mutation 
disrupting ETS and E2F sites together lowered promoter activity in the presence of 
EWS-FLI1 to a level similar to that observed after EWS-FLI1 knockdown in the 
wildtype construct, thus rendering the ATAD2 promoter completely unresponsive to 
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EWS/FLI1 modulation. This result suggests that both ETS and E2F motifs contribute 
to ATAD2 promoter regulation by EWS/FLI1. 
 
Figure 19: ATAD2 promoter study. Fold changes in reporter activity of wildtype and mutant ATAD2 
reporter constructs in the presence (+) and doxycycline-induced absence (-) of EWS/FLI1 48h after 
EWS/FLI1 shRNA induction. Y-axis presents promoter activity relative to untreated control conditions. 
ETS binding site in the ATAD2 promoter at 33/35 and 81 E2F binding sites at -267/-265 were mutated. 
Data represent means and standard deviations of at least three independent experiments, each 
performed in triplicate. 
 
To verify the ChIP-seq results for EWS-FLI1 and E2F3, standard ChIP followed by 
PCR was performed for the ATAD2 promoter. Reduction of EWS-FLI1 and E2F3 
binding upon knockdown of EWS-FLI1 was demonstrated. A control region where 
both EWS-FLI1 and E2F3 should not bind shows no PCR product (Fig. 20).  
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Figure 20: Occupancy of the ATAD2 promoter by EWS-FLI1 and E2F3. To monitor binding of 
EWS-FLI1 and E2F3 to the promoter region of ATAD2, chromatin immunoprecipitation was performed 
in A673 Ewing Sarcoma cells. Cells were either left untreated (+) for control, or were treated for 48h 
with doxycycline to induce knockdown of EWS-FLI1 (-). Two regions containing putative E2F binding 
sites (-350/-240 and -117/18), one region containing putative ETS binding sites (26/129) and a region 
4kb upstream of the TSS (-1678/-1470) not containing E2F or ETS binding sites were amplified. 
3.9 E2F3 is exchanged for E2F4 after knockdown of EWS-FLI1 
According to the before mentioned ChIP-seq data, the activating E2F factor E2F3 
and the repressive E2F factor E2F4 bind to the same promoters of approximately 140 
genes. Because of their supposed counteracting effects we wanted to investigate 
why they are jointly binding the same promoters. Therefore, we performed ChIPs for 
E2F3 and E2F4 before and at different time points after the doxycycline induced 
knockdown of EWS-FLI1 in A673 cells and exemplarily investigated the occupancy of 
the E2F3 and RAD51 promoters.  
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ChIP assays revealed strong binding of E2F3 and a weak occupancy of the E2F3 
promoter by E2F4 in the presence of EWS-FLI1. With increasing time and reduction 
of EWS-FLI1, the occupancy of the E2F3 promoter by E2F3 itself decreased while 
E2F4 increased. While this exchange of E2F3 for E2F4 on the E2F3 promoter 
happened gradually over time with a complete exchange 48h after knockdown of 
EWS-FLI1, the occupancy of the 5’UTR of E2F3 by E2F4 vanished at 48h after 
knockdown of EWS-FLI1 (Fig. 21A). The binding pattern of E2F3 and E2F4 on the 
RAD51 promoter resembled the E2F3 promoter occupancy (Fig. 21B) except that 
E2F3 binding decreased to a higher degree earlier in the time course of EWS-FLI1 
knockdown, while E2F4 increased at a later time point.  
 
Figure 21: Occupancy of the E2F3 and RAD51 promoters by E2F3 and E2F4. Chromatin 
Immunoprecipitations were performed in A673 cells before and at several time points after induction of 
EWS-FLI1 knockdown. A) Three overlapping regions of the E2F3 promoter containing E2F and ETS 
binding sites (-272/-149, -123/62 and 131/262) and a region 1.4kb upstream of the TSS (-1457/-1334) 
not containing E2F or ETS binding sites were amplified. B) Four overlapping regions of the RAD51 
promoter containing E2F and ETS binding sites  (-186/-51, -93/104, -51/65 and 45/146) and a region 
4kb upstream of the TSS (-4270/-4017) not containing E2F or ETS binding sites were amplified. Red 
arrows indicate an ETS binding site, blue arrows an E2F binding site. 
3.9.1 The E2F3/E2F4 exchange is independent of cell cycle 
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Considering the observations of Hu et al. [77] that knockdown of EWS-FLI1 
modulates cell cycle, thereby inducing cell cycle arrest, and those of Takashi et al. 
who demonstrated a cell cycle dependent occupancy of several promoters by E2F4 
[59], we wanted to examine whether the replacement of E2F3 for E2F4 might be due 
to the G1 arrest induced by EWS-FLI1 knock down. Cell cycle analysis before and at 
several time points after knockdown of EWS-FLI1 in A673 cells revealed increasing 
G1 arrest over time, starting with 47% and resulting in a maximum of 85% cells in G1 
arrest after 48h (Fig. 22). To analyze E2F3 binding in the presence of EWS-FLI1 but 
in a comparable G1 arrest situation like the absence of EWS-FLI1 we induced G1 
arrest with two different methods resulting in a 65% G1 arrest using a double 
thymidine block approach and a 77% G1 arrest by transfection of p57, which inhibits 
all G1/S-phase cyclin-CDK complexes [104]. ChIP experiments were performed 
using an antibody against E2F3 in untreated control cells, in cells with double 
thymidine block, and in cells transfected with p57. Both cell cycle inhibiting 
treatments had no influence on the occupancy of the E2F3 and RAD51 promoter by 
E2F3, indicating that the observed exchange is not due to cell cycle arrest but 
dependent on EWS-FLI1 (Fig 23).  
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Figure 22: Cell cycle analysis. A673 cells were either left untreated, treated with doxycycline for 16h, 
24h, 36h or 48h, treated with thymidine or transfected with p57. The diagram shows a representative 
experiment.  
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 Figure 23: Occupancy of the E2F3 and RAD51 promoter by E2F3 before and after cell cycle 
arrest induction. To monitor binding of E2F3 to the promoter region of E2F3 and RAD51 with and 
without induction of a G1 arrest, chromatin immunoprecipitation was performed in A673 Ewing 
Sarcoma cells. Cells were either left untreated (-) for control, or were treated with thymidine or 
transfected with a p57 expression plasmid (+). Two regions for both E2F3 and RAD51 containing 
putative E2F binding sites were amplified. 
To further test functional consequences of a thymidine induced cell cycle arrest, we 
performed gene reporter assays with RAD51 and E2F3 promoter constructs. Figure 
24 shows that treatment of cells with thymidine and subsequent cell cycle arrest had 
no effect on the luciferase activity of all tested promoter constructs compared to 
untreated controls.  
Taken together these results suggest that not only the exchange of E2F3 for E2F4 is 
cell cycle independent, but also the transcriptional activity of the E2F3 and RAD51 
promoter is not changing upon induction of a G1 arrest.  
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 Figure 24: E2F3 and RAD51 promoter construct activity is not changing upon G1 arrest 
induction. Firefly luciferase reporter assays for RAD51 and E2F3 wildtype and mutant promoter 
constructs. Fold changes in reporter activity of wild type and mutant RAD51 and E2F3 reporter 
constructs in the untreated control (-) and Thymidine treated (+) A673 cells. ETS binding sites in the 
RAD51 promoter at -70/-68 and 81/83 and in the E2F3 promoter at -7/-5 and 207/209 and one E2F 
binding site in the RAD51 promoter at 8/11 were mutated. Y-axis presents promoter activity relative to 
untreated control conditions. Data represent means and standard deviations of at least three 
independent experiments, each performed in triplicate. 
3.10 EWS-FLI1 is the main cell cycle regulator 
It was previously described that knockdown of EWS-FLI1 induces a strong cell cycle 
arrest. Based on these data and the fact that E2F1 and E2F3 are known to promote 
cell cycle progression from G1 to S phase, we were interested in whether knockdown 
of E2F1 and or E2F3 might enhance a G1 arrest [76, 77].  
As depicted in Figure 25A, already 50% of A763 cells are in G1 under control 
treatment conditions. Knock down of either E2F1, or E2F3 or both simultaneously in 
A673 cells did not change the percentage of cells in G1 phase.  
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These data suggest that up-regulation of the cell cycle regulators E2F1 and E2F3 
has no effect on cell cycle phase distribution. Therefore we conclude that EWS-FLI1 
is the major regulator of cell cycle in Ewing Sarcoma.  
 
Figure 25: Cell cycle analysis after E2F modulation. A) A673 cells were transfected either with 
shScrambled as a control, shE2F1, shE2F3 or shE2F1+shE2F3. Diagram shows a representative 
experiment. B) Western Blot for A673 cells transfected either with shScrambled as a control, shE2F1, 
shE2F3 or shE2F1+shE2F3. 
3.11 E2F3 binding is dependent on EWS-FLI1 binding 
To test if EWS-FLI1 binding directly affects E2F3 recruitment to their shared target 
gene promoters, we assessed E2F3 occupancy of wildtype and ETS binding site 
mutated promoters of E2F3 and GEMIN4 on transfected constructs by chromatin 
immunoprecipitation. Prohibition of ETS factor binding to the E2F3 promoter by 
mutation of the conserved ETS binding sites at -7 and +207 led to a significant 
decrease of E2F3 binding in A673 but not in HeLa cells used as an EWS/FLI1 
negative control. A similar result was obtained for the binding of E2F3 to the GEMIN4 
promoter when the two ETS binding motifs at -176 and -92 were disrupted (Fig. 26). 
This suggests that EWS-FLI1 binding is necessary for the recruitment of E2F3 at 
these sites on both tested promoters. 
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Figure 26: Occupancy of the E2F3 and GEMIN4 promoter by E2F3 in the presence and absence 
of an intact ETS binding site. Binding of E2F3 to the promoters of E2F3 and GEMIN4 is significantly 
reduced in the Ewing Sarcoma cell line A673 when the ETS recognition site is mutated in comparison 
to the wildtype sequence. In HeLa cells, mutation of the ETS recognition site does not change E2F3 
binding. 
3.12 Pocket proteins reflects binding pattern of their interaction 
partners 
Pocket proteins are, as described in chapter 1.2.4, regulators of E2F factors and 
thereby of the cell cycle. According to the literature E2F3 forms a complex with RB, 
and E2F4 with p130. Therefore, we were interested in whether RB and p130 show 
the same promoter occupancy pattern as their interaction partners [56, 57]. To test 
this, we assessed E2F3, E2F4, RB and p130 promoter occupancy by ChIP followed 
by quantitative RT-PCR (Fig. 27). Although the results showed a high variability 
between the different promoters, overall RB binding to the various tested promoters 
was reduced upon knockdown of EWS-FLI1 as was binding of its interaction partner 
E2F3. In contrast binding of p130 in combination with E2F4 was induced after EWS-
FLI1 depletion. These findings indicate that RB and p130, the regulatory pocket 
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proteins of E2F3 and E2F4, show the same promoter occupancy as their interaction 
partners and that the pocket proteins are involved in the regulation of the tested 
genes. 
 
Figure 27: Occupancy of target gene promoters by pocket proteins and E2Fs. The occupancy by 
RB along with E2F3 of the promoter of ATAD, RAD51 and E2F3 was reduced upon knockdown of 
EWS-FLI1. Binding of p130 along with E2F4 was enhanced upon EWS-FLI1 depletion.  
3.13 Complex formation in Ewing Sarcoma 
According to our results it is clear that EWS-FLI1 leads to the exchange of E2F3 for 
E2F4 and that binding of EWS-FLI1 is necessary for this exchange. Furthermore 
ChIPs for pocket proteins revealed that they bind together with their interaction 
partner to the tested promoters, suggesting that pocket proteins are also involved in 
this regulatory mechanism. However, so far, it is not known how this exchange is 
achieved. One possible mechanism for this interplay could be a physical interaction 
of the EWS-FLI1 protein with any of the E2F/pocket protein complex members. In 
order to test for complex formation between the different components, we performed 
Co-Immunoprecipitations (Co-IP) for the different components followed by Western 
Blots.  
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 Figure 28: EWS-FLI1 does not form a complex with the tested E2F factors or pocket proteins. 
Co-IPs in the presence and absence of EWS-FLI1 for FLI1 and E2F3 were performed as well as 
Western Blots using E2F3, E2F4, RB, p130 and FLI1 Abs. 
Co-IPs for FLI1 showed no interaction with any of the tested possible complex 
partners. E2F3 IP followed by a Western Blot probing with a FLI1 antibody did not 
reveal a signal either (Fig. 28). 
 
Figure 29: Pocket proteins form complexes with E2F factors. Co-IPs in the presence and absence 
of EWS-FLI1 for RB, p130 and DP1 were performed as well as Western Blots using E2F3, E2F4, p130 
and FLI1 Abs. 
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RB IP validated the interaction with E2F3 in the presence of EWS-FLI1, but not in its 
absence, which is a consequence of the down-regulation of E2F3 upon knock down 
of EWS-FLI1 (Fig. 29). No obvious interaction of RB with FLI1 or E2F4 was detected. 
p130 IP confirmed the complex with E2F4 in the absence of EWS-FLI1 but not in the 
presence. This is in line with the upregulation of p130 upon knock down of EWS-FLI1 
and the increased E2F4 and p130 binding after depletion of EWS-FLI1 on target 
gene promoters. A complex formation of p130 with FLI1 or E2F3 was not identified. 
DP1 interacted with E2F3 in the presence of EWS-FLI1, but in neither case with p130 
or FLI1.  
These results suggest that the EWS-FLI1 protein does not interact directly with 
members of the E2F and pocket protein family.  
3.14 E2F1 does not regulate EWS-FLI1 target genes bound by E2F 
factors 
E2F1 is known to be a strong transcriptional activator and also an EWS-FLI1 
activated gene. It has previously been reported that E2F3 and E2F1 differ in their 
target genes and subsequent functions [105]. To test whether this is also the case in 
Ewing Sarcoma, we performed gene reporter assays. More specifically, E2F1 or 
E2F3 were knocked down and luciferase activity of the E2F3 and RAD51 promoters 
were tested. Both promoter constructs showed that the depletion of E2F1 had no 
significant effect on luciferase activity. In contrast, depletion of E2F3 led to a 
decrease of RAD51 promoter activity by 50% and a reduction by 37% of the E2F3 
promoter activity (Fig. 30).  
These data suggest that E2F1 does not regulate the EWS-FLI1 target genes 
investigated in this study. 
 Figure 30: E2F3 and RAD51 promoter construct activity is reduced upon knock down of E2F3, 
not by E2F1. Fold changes in reporter activity of wild type E2F3 and RAD51 reporter constructs in the 
presence (+) and absence (-) of E2F1 or E2F3. Y-axis presents promoter activity relative to untreated 
control conditions. Data represent means and standard deviations of at least three independent 
experiments, each performed in triplicate.  
3.15 EWS-ETS driven cancers share the same regulatory 
mechanism 
Oncogenic fusion genes involving an ETS transcription factor have been described in 
a number of different cancer types, like in acute lymphoblastic leukemia and prostate 
cancer [27, 28]. In our model we propose that EWS-FLI1 binding is essential for E2F 
binding. Since EWS-FLI1 and for example the prostate cancer fusion protein 
TMPRSS2-ERG both bind to ETS binding sites, we wanted to elucidate whether a 
similar mechanism regulates target genes in prostate cancer.  
For this reason we integrated data of published gene expression profiles from a 
TMPRSS2-ERG knockdown experiment in the prostate cancer cell line VCaP into our 
own data set [106, 107]. We identified a shared set of ETS fusion gene binding sites 
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in Ewing Sarcoma and prostate cancer which exhibit colocalization with E2F3 in both 
tumor types. In addition we found a significant overlap in these two systems in gene 
expression responses to the depletion of their respective ETS fusion oncoproteins.  
To functionally validate the in silico data we assessed E2F3 occupancy of wildtype 
and ETS binding site mutated promoters of E2F3 and GEMIN4 on transfected 
constructs by ChIP as described in 3.11. Mutation of the ETS binding motifs and 
consequently prevention of TMPRSS2-ERG binding to the promoters of E2F3 and 
GEMIN4 resulted in decreased E2F3 binding in the prostate cancer cell line VCaP 
(Fig. 31).  
 
Figure 31: Occupancy of the E2F3 and GEMIN4 promoter by E2F3 in the presence and absence 
of an ETS binding site in a prostate cancer cell line. Binding of E2F3 to the promoters of E2F3 and 
GEMIN4 is significantly reduced in the prostate cancer cell line VCaP when the ETS recognition site is 
mutated in comparison to the wild type sequence.  
These data suggest that, just like in Ewing Sarcoma the binding of the ETS fusion 
gene in prostate cancer cells is necessary for the recruitment of the cell cycle 
regulator E2F3.  
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4 Discussion 
EWS-FLI1 dependent regulation of E2F  
A major hallmark of oncogenesis is the deregulation of cell cycle genes in order to 
promote proliferation of cancer cells [108]. According to our ChIP-seq data, EWS-
FLI1 binds to several members of the E2F transcription factor family which are major 
regulators of the cell cycle. Here, we demonstrated direct binding of EWS-FLI1 to the 
E2F3 promoter via ChIP-PCR, the ability of EWS-FLI1 to transcriptionally activate 
E2F3 was proven by gene reporter assays. Strikingly, E2F3 belongs to the group of 
immediate early EWS-FLI1 responsive genes. Additionally, ChIP assays showed 
binding of E2F3 to its own promoter indicating that EWS-FLI1 further drives the up-
regulation of E2F3 by increasing E2F3 levels, followed by binding of E2F3 to its 
promoter and subsequent transcriptional activation. Together with the highly 
significant ChIP-seq overlap, this suggests that EWS-FLI1 and E2F3 are components 
of a feed-forward loop. More specifically, the transcription factor EWS-FLI1 up-
regulates the transcription factor E2F3, followed by the combinatorial binding of 
EWS-FLI1 and E2F3 on their shared target genes including E2F3 thereby jointly 
activating their transcription [109]. This assumption is strengthened by our 
observation that mutation of the ETS binding site in promoters regulated by EWS-
FLI1 in A673 results in decreased E2F3 occupancy. We therefore conclude that the 
binding of EWS-FLI1 is indeed necessary for the binding of E2F3.  
Furthermore, by active recruitment of E2F3 by EWS-FLI1 to promoters of their 
shared target genes, EWS-FLI1 binding leads to E2F4 replacement by E2F3 and 
activates gene expression of the corresponding genes.  
The results of an earlier study by Freedman et al. in fact support our model. In their 
study they demonstrated that E2F factors can either bind to distinct activating or 
repressive E2F sites such as in the Cdc2 promoter [110, 111] or, alternatively, 
activating and repressing E2Fs can bind to the same binding site as in the Cdc6 
promoter. In the latter case interaction with further binding partners determines the 
fate of target gene expression. For both types of promoters, Freedman et al. 
performed ChIP assays on promoter constructs at the G1/S transition of the cell 
cycle. By mutation of the activating E2F binding site, they showed binding of E2F4 to 
the repressive E2F site, whereas the introduction of a YY1 binding element 
diminished E2F4 binding and enabled E2F3 to bind to Cdc2 and Cdc6 promoters. 
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Mutation of the YY1 binding site again shifted binding from the activating E2F3 to the 
repressing E2F4, indicating that the regulation is not determined by the sequence of 
the binding site or the cell cycle status, but by the context and the binding partners of 
E2F [111]. Since ETS binding sites significantly co-occur with E2F binding sites on 
EWS-FLI1 activated genes and ChIP-seq hits for EWS-FLI1, E2F3 and E2F4 
overlap, we propose that EWS-FLI1 is such an activating co-factor and thereby 
regulating E2F target genes.  
A recent study by Li et al. showed an androgen-dependent switch of E2F1 and E2F4 
on the cyclin B promoter in prostate stromal cells. Stimulation with androgens leads 
to a displacement of E2F1 for E2F4 by the androgen receptor, resulting in 
recruitment of repressive complexes. The exchange coincides with direct interaction 
of the androgen receptor and E2F1. In contrast to our results, interaction with 
members of the pocket protein family and binding of E2F3 to the promoter was not 
observed. The involvement of E2F1 in contrast to E2F3 plus pocket proteins in our 
study might be due to the different cellular systems. While Li et al. used non-
cancerous prostate stromal cells, we investigated a Ewing Sarcoma and a prostate 
cancer cell line, both harboring an ETS driven oncogenic transcription factor. Li and 
colleagues also analyzed the involvement of cyclin B in LNCaP cells, an ETS fusion 
positive prostate cancer cell line, and did not observe a response due to androgen 
treatment [112]. 
 
Our data are consistent with a model in which EWS-FLI1 actively recruits an 
activating E2F factor thereby replacing a repressing E2F factor and in which EWS-
FLI1 binding is essential for E2F binding. 
 
E2F recruitment to shared target gene promoters 
The actual mechanism by which EWS-FLI1 recruits E2F3 still remains unclear. Data 
from our ChIP-seq study showed that E2F and EWS-FLI1 binding sites are 
distributed in a specific pattern. The length of DNA between E2F and EWS-FLI1 
binding motifs is in line with the length of DNA associated with single nucleosome 
plus one (or two) linker DNA sequences. This suggests that geometric constraints or 
a form of nucleosome-mediated cooperativity contribute to the selection of referred 
configurations [113].  
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It is conceivable that the binding of EWS-FLI1 leads to a change in nucleosome 
formation, opening up the chromatin structure and resulting in the binding of E2F3. 
The ability of ETS transcription factors to bend DNA and enhance promoter activation 
has already been described for ETS1. For instance, it has been reported that binding 
of either p51 or p42 isoforms of ETS1 to the Stromelysin 1 promoter results in 
different DNA bending and consequently promoter activation. While p51 induces a 
bend directed away from the protein–DNA interface and fully trans-activates the 
Stromelysin-1 promoter, p42 generates an opposite bend and activates the promoter 
only weakly [114].  
The regulation of pocket proteins by EWS-FLI1 would be another possible 
mechanism. According to our data, Rb is regulated along with its binding partner 
E2F3 and p130 along with E2F4, emphasizing their cooperativity. Although we could 
not show that EWS-FLI1 is in a complex with the pocket proteins or E2F3 or E2F4, it 
is still possible that it interacts with Rb leading to the release of E2F3 from the 
repressive Rb-E2F-HDAC complex, thereby inducing expression of target genes [68]. 
This notion is further supported by a study reporting that the N-terminal region of 
EWS-FLI1 associates with HDAC1 to form a complex with p53 and inhibit its function 
[115]. Supposedly EWS-FLI1 interacts with HDAC in the Rb-E2F complex and either 
disrupts the complex, leading to target gene expression, or uses its interaction with 
HDAC to attract the complex to its own target genes.  
Another possible interaction partner mediating the complex formation of EWS-FLI1 
and E2F family members might be host cell factor 1 (HCF-1). Unpublished data from 
Jeff Toretsky’s lab revealed an interaction of EWS-FLI1 with HCF-1 (personal 
communication). HCF-1 is not binding directly to DNA but shows chromatin 
association activity via its Kelch domain, which promotes binding of HCF to the HCF-
1 binding motif (HBM) in DNA binding proteins. A single mutation within this domain 
leads to loss of binding and G1 arrest. Strikingly, pRB inactivation leads to a release 
from the G1 arrest, suggesting that HCF-1 regulates G1 phase progression via 
counteraction of one or several pocket proteins. Furthermore, it was demonstrated 
that HCF-1 is associated with several members of the E2F family, both with 
activators and repressors [116-119]. Together, this suggests that HCF-1 is involved 
in E2F mediated transcriptional activation and repression, and therefore may 
represent an intriguing candidate for the missing link between EWS-FLI1 and E2F 
family members.  
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Although the actual mechanism by which EWS-FLI1 recruits E2F3 and replaces 
E2F4 in the progenitor cell of Ewing Sarcoma still remains unknown, we propose 
several possible alternative mechanisms: DNA bending due to binding of EWS-FLI1, 
regulation of pocket proteins, or interaction with a complex partner of E2F factors 
such as HCF-1. 
 
EWS-FLI1 deregulates the cell cycle 
A previous study reported that knock down of EWS-FLI1 arrests cells in G1 [76, 77]. 
Due to the fact that E2Fs are major regulators of cell cycle progression we wanted to 
explore the consequences of their depletion or of overexpression on cell cycle arrest. 
We found that in Ewing Sarcoma cell lines, EWS-FLI1 is the master regulator of the 
cell cycle and neither overexpression nor depletion of E2F factors affects the cell 
cycle phase distribution. This is in line with our gene expression profiling of A673 
cells with E2F1, E2F3 or EWS-FLI1 knockdown. Based on these data EWS-FLI1 
activated targets annotate to cell cycle genes. Genes activated by both EWS-FLI1 
and E2F3 also annotate to cell cycle genes, whereas genes down-regulated after 
knock down of E2F1 and E2F3 individually and simultaneously do not annotate to 
cell cycle, indicating that EWS-FLI1 is required for cell cycle regulation.  
Additionally no cell cycle induced occupation of promoters by E2F4 as reported by 
Takahashi et al. could be shown in Ewing Sarcoma [59]. Enforced cell cycle arrest of 
Ewing Sarcoma cells in the presence of EWS-FLI1 did not show reduced binding of 
E2F3, suggesting that the exchange of E2F3/4 is not a cell cycle artifact, but rather 
EWS-FLI1 dependent.  
Therefore, we propose a model in which EWS-FLI1 actively recruits E2F3 to target 
genes in the progenitor cell of Ewing Sarcoma and induces an irreversible switch in 
the gene expression profile which can only be altered through the depletion of EWS-
FLI1 but not completely through modulation of E2F family members.  
Results from our previous study already revealed that EWS-FLI1 activated genes are 
significantly enriched in cell cycle functions [11]. Here we could validate a number of 
cell cycle regulating genes to be direct targets of EWS-FLI1 and additionally, also to 
be regulated by E2F3. One of these target genes is CDK2, a master regulator of 
G1/S transition (see chapter 1.2.2). CDK2 and its corresponding cyclin phosphorylate 
and inactivate Rb, thereby releasing it from the repression complex with E2F family 
members and allowing the transcription of genes necessary for driving the G1/S 
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transition. Recently it has also been shown that loss of CDK2 results in enhanced 
neuronal differentiation, whereas in Ewing Sarcoma CDK2 is overexpressed and 
differentiation is decreased [1, 76, 77, 120].  
SKP2 overexpression is associated with a variety of cancers and is involved in G1/S 
transition [121]. Recently, our lab reported on a tumor suppressive mechanism in 
Ewing Sarcoma mediated through FOXO1, which is in turn negatively regulated by 
SKP2 and also CDK2. In this study we show that SKP2 is a direct target of EWS-FLI1 
(see chapter 3.3), resulting in enhanced cell proliferation as well as suppression of a 
tumor suppressor in Ewing Sarcoma. As already discussed, E2F3, along with several 
other E2F family members is as well regulated by EWS-FLI1 and E2F3.  
 
In line with the data from Kauer et al., we report here that EWS-FLI1 actively 
deregulates cell cycle progression in Ewing Sarcoma. Additionally, it deregulates E2F 
family members which are themselves major regulators of the cell cycle [11, 53]. This 
mechanism leads to enhanced proliferation, consequently tumor growth and 
ultimately tumor progression. Additionally we suggest that EWS-FLI1 actively recruits 
E2F3 to target genes in the cell of origin of Ewing Sarcoma and induces an 
irreversible switch in the gene expression profile. In fact, only the depletion of EWS-
FLI1 seems to be able to reverse that profile. 
 
ETS fusion driven cancers – prostate cancer 
Since binding of EWS-FLI1 to the ETS binding site is the initial step and the 
prerequisite of our proposed model, we decided to elucidate whether the mechanism 
found in Ewing Sarcoma is also applicable to another ETS fusion driven cancer. ETS 
oncogenic fusion genes are known to be involved in several types of cancer. One of 
those, with the most frequent ETS fusions, is prostate cancer, in which more than 
50% of cases show a rearrangement involving TMPRSS2 and an ETS transcription 
factor [27].  
Strikingly, integrating data of published gene expression profiles from a TMPRSS2-
ERG knockdown experiment in VCaP into our own data set, identified a shared set of 
ETS fusion gene binding sites in Ewing Sarcoma and prostate cancer which exhibit 
colocalization with E2F3 in both tumor types [106, 107]. The importance of this result 
was strengthened by our demonstration of a significant overlap in the gene 
expression responses of these two systems to depletion of their respective ETS 
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fusion oncoproteins. Additionally, we demonstrated that the binding of the ETS fusion 
gene TMPRSS2-ERG is necessary for the recruitment of the cell cycle regulator 
E2F3 in the prostate cancer cell line VCaP.  
These observations suggest that the functional EWS-FLI1/E2F3 module in Ewing 
Sarcoma is shared to a significant extent between these diseases and that it may be 
in part responsible for the oncogenic activity of their respective ETS factors.  
 
Conclusion 
Understanding the mechanisms of EWS-FLI1 driven gene regulation is essential to 
understand Ewing Sarcomagenesis and is the key to develop new treatment 
strategies. 
In this thesis I confirm that EWS-FLI1 is a transcriptional regulator via direct and 
indirect mechanisms. More specifically I show that EWS-FLI1 up-regulates the 
transcription factor E2F3, followed by the combinatorial binding of EWS-FLI1 and 
E2F3 on their shared target genes. Interestingly both factors bind within the E2F3 
promoter region itself confirming the establishment of a feed-forward loop. 
Furthermore, by active recruitment of E2F3 by EWS-FLI1 to promoters of their 
shared target genes, EWS-FLI1 binding leads to E2F4 replacement for E2F3, in the 
progenitor cell of Ewing Sarcoma, and activates gene expression of the 
corresponding genes (Fig. 32).  
Strikingly, the functional E2F/ETS transcriptional module detected in Ewing Sarcoma 
for the chimeric ETS factor EWS-FLI1 was found to be also relevant to TMPRSS2-
ERG expressing prostate cancer cells. Our findings in a paediatric tumor may 
therefore also be of relevance to one of the most frequent human cancers and 
suggest that an ETS-E2F transcriptional module may be a general feature of ETS 
driven cancers.  
 
 
Figure 32: Model of target gene regulation by EWS-FLI1 and E2F factors. EWS-FLI1 replaces 
E2F4 by E2F3 on their shared target genes including E2F3, up-regulates the transcription factor E2F3, 
followed by the combinatorial binding of EWS-FLI1 and E2F3 on further target genes.  
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